0001213900-22-071487.txt : 20221114 0001213900-22-071487.hdr.sgml : 20221114 20221114062202 ACCESSION NUMBER: 0001213900-22-071487 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 221379787 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 10-Q 1 f10q0922_inmedpharma.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 001-39685

 

INMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   98-1428279
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

  V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

(604) 669-7207

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐     No

 

As of November 14, 2022, the registrant had 936,761 common shares, without par value, outstanding.

 

 

 

 

 

INDEX

 

  Page
PART I – FINANCIAL INFORMATION
 
ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 1
   
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 23
   
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 35
   
ITEM 4. CONTROLS AND PROCEDURES 35
   
PART II – OTHER INFORMATION
 
ITEM 1. LEGAL PROCEEDINGS 36
   
ITEM 1A. RISK FACTORS 36
   
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 36
   
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 36
   
ITEM 4. MINE SAFETY DISCLOSURE 36
   
ITEM 5. OTHER INFORMATION 36
   
ITEM 6. EXHIBITS 36
   
SIGNATURES 37

 

i

 

 

PART I

 

ITEM 1. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS.

 

 

Unaudited Condensed Consolidated Interim Financial Statements of

 

InMed Pharmaceuticals Inc.

 

For the Three Months Ended September 30, 2022 and 2021

 

Suite 310 – 815 West Hastings Street

Vancouver, BC, Canada, V6C 1B4

Tel: +1-604-669-7207

 

1

 

 

 

InMed Pharmaceuticals Inc.

(Expressed in U.S. Dollars)

September 30, 2022

 

INDEX   Page 
       
Financial Statements (Unaudited)    
       
Condensed Consolidated Interim Balance Sheets   3
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss   4
Condensed Consolidated Interim Statements of Shareholders’ Equity   5
Condensed Consolidated Interim Statements of Cash Flows   6
Notes to the Condensed Consolidated Interim Financial Statements   7-19

 

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

 

2

 

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited)
As at September 30, 2022 and June 30, 2022

Expressed in U.S. Dollars

 

 

 

       September 30,   June 30, 
   Note   2022   2022 
       $   $ 
ASSETS            
Current            
Cash and cash equivalents        9,350,427    6,176,866 
Short-term investments        42,125    44,804 
Accounts receivable        15,169    88,027 
Inventories   4    1,778,523    2,490,854 
Prepaids and other assets        356,665    797,225 
Total current assets        11,542,909    9,597,776 
                
Non-Current               
Property, equipment and ROU assets, net   5    802,369    904,252 
Intangible assets, net   6    2,067,922    2,108,915 
Other assets        171,130    176,637 
Total Assets        14,584,330    12,787,580 
                
LIABILITIES AND SHAREHOLDERS’ EQUITY               
Current               
Accounts payable and accrued liabilities   7    2,362,190    2,415,265 
Current portion of lease obligations   10    404,163    404,276 
Deferred revenue        15,700    - 
Acquisition consideration payable        500,000    500,000 
Total current liabilities        3,282,053    3,319,541 
                
Non-current               
Lease obligations   10    294,337    389,498 
Total Liabilities        3,576,390    3,709,039 
                
Shareholders’ Equity               
Common shares, no par value, unlimited authorized shares:               
908,766 (June 30, 2022 - 650,667) issued and outstanding   8    72,671,392    70,718,461 
Additional paid-in capital   8, 9    35,170,766    31,684,098 
Accumulated deficit        (96,962,787)   (93,452,587)
Accumulated other comprehensive income        128,569    128,569 
Total Shareholders’ Equity        11,007,940    9,078,541 
Total Liabilities and Shareholders’ Equity        14,584,330    12,787,580 

 

Going Concern (Note 1)

Commitments and Contingencies (Note 14)

Related Party Transactions (Note 16)

Subsequent Events (Note 17)

 

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

 

3

 

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)

For the three months ended September 30, 2022 and 2021

Expressed in U.S. Dollars

 

 

 

       Three Months Ended 
       September 30 
   Note   2022   2021 
       $   $ 
             
Sales        320,788    - 
Cost of sales        235,034    - 
Inventory write-down   4    576,772    - 
Gross loss        (491,018)   - 
                
Operating Expenses               
Research and development and patents        1,378,653    1,491,252 
General and administrative        1,560,477    1,372,867 
Amortization and depreciation   5, 6    49,048    28,532 
Total operating expenses        2,988,178    2,892,651 
                
Other Income (Expense)               
Interest and other income        72,587    5,148 
Foreign exchange loss        (96,791)   (84,112)
Loss before income taxes        (3,503,400)   (2,971,615)
                
Tax expense        (6,800)   - 
Net loss for the period        (3,510,200)   (2,971,615)
                
Net loss per share for the period               
Basic and diluted   11    (4.06)   (6.17)
Weighted average outstanding common shares               
Basic and diluted   11    865,619    481,902 

 

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

 

4

 

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF SHAREHOLDERS’ EQUITY (unaudited)
For the three months ended September 30, 2022 and 2021

Expressed in U.S. Dollars

 

 

 

                   Accumulated     
               Additional       Other     
               Paid-in   Accumulated   Comprehensive     
   Note   Common Shares   Capital   Deficit   Income   Total 
       #   $   $   $   $   $ 
Balance June 30, 2021        322,028    60,587,417    21,513,051    (74,852,470)   128,569    7,376,567 
Private placement        35,600    1,459,051    10,540,635    -    -    11,999,686 
Share issuance costs        -    (247,336)   (1,786,831)   -    -    (2,034,167)
Agents’ warrants        -    -    739,920    -    -    739,920 
Exercise of pre-funded warrants        55,453    1,887,592    (1,887,453)   -    -    139 
Loss for the period        -    -    -    (2,971,615)   -    (2,971,615)
Share-based compensation   9    -    -    111,142    -    -    111,142 
Balance September 30, 2021        413,081    63,686,724    29,230,464    (77,824,085)   128,569    15,221,672 
                                    
                   Accumulated     
               Additional       Other     
               Paid-in   Accumulated   Comprehensive     
   Note   Common Shares   Capital   Deficit   Income   Total 
       #   $   $   $   $   $ 
Balance June 30, 2022        650,667    70,718,461    31,684,098    (93,452,587)   128,569    9,078,541 
Private placement   8    90,000    410,376    5,589,570    -    -    5,999,946 
Share issuance costs   8    -    (77,242)   (1,052,101)   -    -    (1,129,343)
Agents’ investment options        -    -    451,897    -    -    451,897 
Exercise of pre-funded warrants   8    168,099    1,619,797    (1,619,378)   -    -    419 
Loss for the period        -    -    -    (3,510,200)   -    (3,510,200)
Share-based compensation   9    -    -    116,680    -    -    116,680 
Balance September 30, 2022        908,766    72,671,392    35,170,766    (96,962,787)   128,569    11,007,940 

 

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

 

5

 

 

InMed Pharmaceuticals Inc.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited)

For the three months ended September 30, 2022 and 2021

Expressed in U.S. Dollars

 

 

 

   Note   2022   2021 
       $   $ 
Cash provided by (used in):          
             
Operating Activities            
Net loss for the period        (3,510,200)   (2,971,615)
Items not requiring cash:               
    Amortization and depreciation   5, 6    49,048    28,532 
    Share-based compensation   9    116,680    111,142 
    Amortization of right-of-use assets        99,460    25,906 
    Interest income received on short-term investments        (120)   (23)
    Unrealized foreign exchange loss        2,796    1,262 
    Inventory write-down   4    576,772    - 
Payments on lease obligations        (100,903)   (17,411)
Changes in non-cash working capital:               
    Inventories        135,559    - 
    Prepaids and other assets        440,560    634,410 
    Other non-current assets        5,507    6,030 
    Accounts receivable        72,858    (2,923)
    Accounts payable and accrued liabilities        (159,260)   (469,227)
    Deferred revenue        15,700    - 
Total cash used in operating activities        (2,255,543)   (2,653,917)
                
Investing Activities               
    Short-term loan        -    (250,000)
Total cash used in investing activities        -    (250,000)
                
Financing Activities               
    Shares issued for cash   8    6,000,365    11,999,825 
    Share issuance costs   8    (571,261)   (1,115,129)
Total cash provided by financing activities        5,429,104    10,884,696 
Increase (decrease) in cash during the period        3,173,561    7,980,779 
Cash and cash equivalents beginning of the period        6,176,866    7,363,126 
Cash and cash equivalents end of the period        9,350,427    15,343,905 

 

See Note 13 for Non-Cash Transactions

 

The accompanying notes form an integral part of these condensed consolidated interim financial statements.

 

6

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

1.CORPORATE INFORMATION AND CONTINUING OPERATIONS

 

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the Business Corporations Act of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

 

The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s corporate office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.

 

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

 

Through September 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $97.0 million as of September 30, 2022 (June 30, 2022 - $93.5 million). The Company expects to continue to generate operating losses for the foreseeable future.

 

As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash and cash equivalents of $9.4 million as of September 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

 

The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.

 

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.

 

7

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

2.SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2022.

 

These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2022.

 

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “$” and “US$” are to United States (“U.S.”) dollars and references to “C$” are to Canadian dollars.

 

Use of Estimates

 

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.

 

COVID-19 Impacts

 

The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.

 

8

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

2.SIGNIFICANT ACCOUNTING POLICIES (cont’d)

 

Recent Accounting Pronouncements Not Yet Adopted

 

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

 

3.CUSTOMER CONCENTRATION

 

The Company had three customers during the three months ended September 30, 2022, which individually generated 10% or more of the Company’s sales. These customers accounted for 78% of the Company’s sales for the three months ended September 30, 2022. There were no outstanding amounts receivable from these customers as at September 30, 2022.

 

4.INVENTORIES

 

Inventories consisted of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Raw materials   292,577    292,577 
Work in process   1,210,261    1,724,851 
Finished goods   275,685    473,426 
Inventories   1,778,523    2,490,854 

 

During the three months ended September 30, 2022, inventory expensed to cost of goods sold was $235,034 (2021 - $Nil).

 

During the three months ended September 30, 2022, the write-down of inventories to net realizable value was $576,772 (2021 - $Nil). Contributing factors to the decrease in net realizable value included lower demand and downward pricing pressure.

 

5.PROPERTY, EQUIPMENT AND ROU ASSETS, NET

 

Property, equipment and ROU assets consisted of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Right-of-Use Assets (leases)   1,167,436    1,167,436 
Equipment   212,877    212,877 
Leasehold Improvements   40,409    40,409 
Property and equipment   1,420,722    1,420,722 
Less: accumulated depreciation and amortization   (618,353)   (516,470)
Property, equipment and ROU assets, net   802,369    904,252 

 

Depreciation expense on property, equipment and leasehold improvements for the three months ended September 30, 2022, was $8,055 (2021 - $4,217). Amortization expense related to the right-of-use assets for the three months ended September 30, 2022, was $90,244 (2021 - $21,343) and was recorded in general and administrative expenses.

 

9

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

6.INTANGIBLE ASSETS

 

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Intellectual property   1,736,420    1,736,420 
Patents   1,191,000    1,191,000 
Intangible assets   2,927,420    2,927,420 
Less: accumulated depreciation   (859,498)   (818,505)
Intangible assets, net   2,067,922    2,108,915 

 

Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.

 

Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years.

 

As at September 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.

 

Amortization expense on intangible assets for the three months ended September 30, 2022 was $40,993 (2021 - $24,315). The Company expects amortization expense to be incurred over the next five years as follows:

 

   $ 
     
2023   155,778 
2024   155,778 
2025   155,778 
2026   155,778 
2027   155,778 
    778,890 

 

7.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities consist of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Trade payables   1,096,212    1,166,068 
Accrued research and development expenses   956,429    839,638 
Employee compensation, benefits and related accruals   249,593    139,120 
Accrued general and administrative expenses   59,956    270,439 
Accounts payable and accrued liabilities   2,362,190    2,415,265 

 

10

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

8.SHARE CAPITAL AND RESERVES

 

a)Authorized

 

As at September 30, 2022, the Company’s authorized share structure consisted of: (i) an unlimited number of common shares without par value; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at September 30, 2022 and June 30, 2022.

 

The Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of common shares.

 

b)Common Shares

 

During the three months ended September 30, 2022, the Company completed the following:

 

September 2022 Private Placement Offering:

 

Transaction Description  Number   Issue Price   Total 
Shares Issued   90,000   $8.680   $781,200 
Pre-funded Warrants Issued   601,245   $8.6799    5,218,746 
Gross Proceeds            $5,999,946 
Allocated to Additional Paid-in Capital             (5,589,570)
             $410,376 
Share Issuance Costs            $(77,242)

 

On September 13, 2022, the Company closed a private placement of its common shares and issued an aggregate of 90,000 common shares and 601,245 pre-funded warrants, for gross proceeds of $5,999,946. The pre-funded warrants were determined to be common stock equivalents. Each common share and each pre-funded warrant were sold in the offering with an investment option to purchase a common share. Transaction costs were allocated proportionally between common shares and investment options with $77,242 allocated to common shares and the balance of $1,052,101 allocated to additional paid-in capital and recorded as a component of shareholders’ equity in the consolidated balance sheet. As at September 30, 2022, there were 601,245 pre-funded warrants outstanding.

 

11

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

8.SHARE CAPITAL AND RESERVES (cont’d)

 

c)Share Purchase Warrants

 

The following is a summary of changes in share purchase warrants from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   244,767   $41.99         - 
Cancelled   (179,231)  $18.50    - 
Balance as at September 30, 2022   65,536   $106.23    - 

 

The total intrinsic value of warrants exercised during the three months ended September 30, 2022 was $Nil (2021 - $Nil).

 

d)Agents’ Warrants

 

The following is a summary of changes in agents’ warrants from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   12,109   $92.91         - 
Balance as at September 30, 2022   12,109   $92.91    - 

 

e)Preferred Investment Options

 

On September 13, 2022, 1,382,490 preferred investment options were issued with an exercise price of $8.44 per share, were immediately exercisable upon issuance, and expire 7 years following the date of issuance.

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   233,100   $18.50           - 
Granted   1,382,490   $8.44    - 
Cancelled   (233,100)  $18.50    - 
Balance as at September 30, 2022   1,382,490   $8.44    - 

 

12

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

8.SHARE CAPITAL AND RESERVES (cont’d)

 

f)Agents’ Investment Options

 

On September 13, 2022, 44,931 preferred investment options were issued for services with an exercise price of $10.85 per share, were immediately exercisable upon issuance, and expire approximately 7 years following the date of issuance.

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   15,152   $26.81           - 
Granted   44,931   $10.85    - 
Balance as at September 30, 2022   60,083   $14.88    - 

 

9.SHARE-BASED PAYMENTS

 

a)Option Plan Details

 

On March 24, 2017, and as amended on November 20, 2020, the Company’s shareholders approved: (i) the adoption of a new stock option plan (the “Plan”) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company’s previous stock option plan.

 

As at September 30, 2022, there were 20,300 (June 30, 2022 – 18,163) options available for future allocation pursuant to SEC rules and 20% of the issued and outstanding shares according to the terms of the Plan. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.

 

Stock options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock options are granted with United States dollar exercise prices.

 

13

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

9.SHARE-BASED PAYMENTS (cont’d)

 

a)Option Plan Details (cont’d)

 

The following is a summary of changes in outstanding options from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Exercise Price
$
 
Balance as at June 30, 2022   55,603    128.59 
Granted   560    9.75 
Expired/Forfeited   (2,697)   46.62 
Balance as at September 30, 2022   53,466    124.74 
           
September 30, 2022:          
Vested and exercisable   26,531    212.33 
Unvested   26,935    38.46 

 

b)Fair Value of Options Issued During the Period

 

i)Weighted Average Fair Value at Grant Date of Options Granted:

 

The weighted average fair value at grant date of options granted during the three months ended September 30, 2022, was $6.00 per option (year ended June 30, 2022 - $21.04). Assumptions used for options granted during the three months ended September 30, 2022 included a weighted average risk-free interest rate of 3.59% (year ended June 30, 2022 – 1.17%), weighted average expected life of 3.3 years calculated using the Simplified Method for directors, officers and employees, weighted average volatility factor of 91.61% (year ended June 30, 2022 – 97.15%), weighted average dividend yield of 0% (year ended June 30, 2022 – 0%) and a 5% forfeiture rate (year ended June 30, 2022 – 5%).

 

ii)Expenses Arising from Share-based Payment Transactions:

 

Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2022, were $116,681 (2021 - $111,142). $65,072 was allocated to general and administrative expenses (2021 - $81,009) and the remaining $51,609 was allocated to research and development expenses (2021 - $30,133). Unrecognized compensation cost at September 30, 2022 related to unvested options was $154,239 which will be recognized over a weighted-average vesting period of 0.8 years.

 

14

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

10.LEASE OBLIGATIONS

 

The Company is committed to minimum lease payments as follows:

 

Maturity Analysis  September 30,
2022
 
   $ 
     
Less than one year   338,135 
One to five years   200,655 
More than five years   - 
Total undiscounted lease liabilities(1)   538,790 

 

(1)Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.

 

11.BASIC AND DILUTED LOSS PER SHARE

 

Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are anti-dilutive, they are excluded from the weighted average number of common shares in the table below.

 

   Three Months Ended 
   September 30, 
   2022   2021 
   $   $ 
         
Net loss for the period   (3,510,200)   (2,971,615)
Basic and diluted loss per share   (4.06)   (6.17)
Weighted average number of common shares - basic and diluted   865,619    481,902 

 

12. SEGMENT INFORMATION

 

The following table presents information about the Company’s reportable segments for the three months ended September 30, 2022 and 2021:

 

    Three Months Ended September 30,  
    2022     2021  
    InMed     BayMedica     Total     InMed     BayMedica     Total  
    $     $     $     $     $     $  
                                     
Sales     -       320,788       320,788       -              -       -  
Operating expenses     2,268,831       1,562,157       3,830,988       2,971,615       -       2,971,615  
Net loss     (2,268,831 )     (1,241,369 )     (3,510,200 )     (2,971,615 )     -       (2,971,615 )
Unrestricted cash     9,227,828       122,599       9,350,427       15,343,905       -       15,343,905  

 

15

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

13.NON-CASH TRANSACTIONS

 

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. During the three months ended September 30, 2022, the following transactions were excluded from the statement of cash flows:

 

i)On September 13, 2022, the Company issued 44,931 preferred investment options to its placement agent. The fair value of these investment options was $451,897 and was included in share issuance costs related to the September 2022 private placement.

 

ii)As at September 30, 2022, the Company has unpaid financing costs of $106,185.

 

During the three months ended September 30, 2021, the following transactions were excluded from the statement of cash flows:

 

i)On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $739,920 and was included in share issuance costs related to the July 2021 private placement.

 

ii)As at September 30, 2021, the Company has unpaid financing costs of $179,118.

 

14.COMMITMENTS AND CONTINGENCIES

 

Pursuant to the terms of agreements with various contract research organizations, as at September 30, 2022, the Company is committed for contract research services and materials at a cost of approximately $2,393,075. A total of $1,632,165 of these expenditures are expected to occur in the twelve months following September 30, 2022 and the balance of $760,910 in the following twelve month period.

 

Pursuant to the terms of agreements with various vendors, as at September 30, 2022, the Company is committed for contract materials and equipment at a cost of approximately $563,612, expected to occur in the twelve months following September 30, 2022.

 

Pursuant to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (“UBC”), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the agreement. To date, no payments have been required to be made.

 

Pursuant to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.

 

Pursuant to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable.

 

Short-term investments include guaranteed investment certificates with a face value of $42,125 (June 30, 2022 - $44,676) that are pledged as security for a corporate credit card.

 

16

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

14.COMMITMENTS AND CONTINGENCIES (cont’d)

 

The Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance limits the Company’s liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

 

Pursuant to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase 700 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.

 

The Company entered into a patent license agreement with a third party (the “Licensor”) in an agreement dated February 15, 2021. The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to 2022. As at September 30, 2022, the Company has paid $300,000 for the minimum payments under the agreement.

 

From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.

 

15.FINANCIAL RISK MANAGEMENT

 

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities.

 

The fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs.

 

a)Market Risk:

 

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk. The Company does not currently have significant commodity price risk or equity price risk.

 

17

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

15.FINANCIAL RISK MANAGEMENT (cont’d)

 

a)Market Risk (cont’d):

 

Foreign Currency Risk:

 

Foreign currency risk is the risk that the future cash flows or fair value of the Company’s financial instruments that are denominated in a currency that is not the Company’s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates. Portions of the Company’s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.

 

Accordingly, the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.

 

As at September 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar denominated accounts payable and accrued liabilities of C$1,712,166 which is equivalent to US$1,249,196 at the September 30, 2022 exchange rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases of supplies and services from suppliers in Canada.

 

Each increase (decrease) of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain (loss), with a corresponding effect on cash flows, of $12,492 based on the September 30, 2022 net Canadian dollar assets (liabilities) position. During the three months ended September 30, 2022, the Company recorded foreign exchange loss of $94,392 (2021 – $83,800) related to Canadian dollars.

 

Interest Rate Risk:

 

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at September 30, 2022, holdings of cash and cash equivalents of $8,061,484 (June 30, 2022 - $5,087,615) are subject to floating interest rates. The balance of the Company’s cash holdings of $1,288,943 (June 30, 2022 - $1,089,251) are non-interest bearing.

 

As at September 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $42,125 (June 30, 2022 - $44,676).

 

The Company’s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.

 

18

 

 

INMED PHARMACEUTICALS INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED September 30, 2022 AND 2021

(Expressed in U.S. Dollars)

 

 

 

15.FINANCIAL RISK MANAGEMENT (cont’d)

 

b)Credit Risk:

 

Credit risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents, short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.

 

The carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each reporting date.

 

c)Liquidity Risk:

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s policy is to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation. A key risk in managing liquidity is the degree of uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at September 30, 2022, the Company has cash and cash equivalents and short-term investments of $9,392,552 (June 30, 2022 - $6,221,670), current liabilities of $3,282,053 (June 30, 2022 - $3,181,316) and a working capital surplus of $8,260,856 (June 30, 2022 - $6,416,460).

 

16.RELATED PARTY TRANSACTIONS

 

On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP (“NRF”). During the three months ended September 30, 2022, NRF rendered legal services in the amount of $67,092 (2021 - $Nil) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were rendered by Ms. Grove directly.

 

17.SUBSEQUENT EVENTS

 

On October 13, 2022, in accordance with the BayMedica Agreement, $500,000 of escrow payments were made to BayMedica’s historical equity and convertible debt holders.

 

In October 2022, 341,226 of the September 2022 pre-funded warrants were exercised for a total of $34, resulting in the issuance of 341,226 common shares.

 

19

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities law, which are included but are not limited to statements with respect to InMed Pharmaceuticals Inc.’s (the “Company” or “InMed”) anticipated results and progress of the Company’s operations, research and development in future periods, plans related to its business strategy, and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We may, in some cases, use words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:

 

Our ability to pursue the discovery through to commercialization of Product Candidates and Products that will treat diseases with high unmet medical needs;

 

The continued optimization of cannabinoid manufacturing approaches;

 

Our success in initiating discussions with potential partners for licensing various aspects of our Product Candidates;

 

Our ability to commercialize and, where required, register Product Candidates and Products in the United States and other jurisdictions;

 

Our ability to successfully access existing manufacturing capacity via leases with third-parties or to transfer our manufacturing processes to a contract manufacturing organizations;

 

Our belief that our manufacturing approaches that we are developing are robust and effective and will result in high yields of cannabinoids and will be a significant improvement upon existing manufacturing platforms;

 

Our belief that that INM-755 offers specific advantages and will prove to provide the extensive relief symptomology with the added potential of addressing the underlying disease in EB;

 

The structure and timing of future INM-755 studies including that we will complete patient enrollment into our Phase II study in EB in 2022;

 

The ability of the IntegraSynTM approach to introduce a revenue stream to us before the expected commercial approval of our therapeutic programs;

 

Our ability to successfully scale up our IntegraSynTM or other cost effective approaches so that it will be commercial-scale ready after Phase II clinical trials are completed, after which time we may no longer need to source APIs from API manufacturers;

 

The success of the key next steps in our manufacturing approaches, including continuing efforts to diversify the number of cannabinoids produced, scaling-up the processes to larger vessels and identifying external vendors to assist in the commercial scale-up of the process;

 

Our ability to successfully make determinations as to which research and development programs to continue based on several strategic factors;

 

Our ability to monetize our IntegraSynTM manufacturing approach to the broader pharmaceutical industry;

 

20

 

 

Our ability to continue to outsource the majority of our research and development activities through scientific collaboration agreements and arrangements with various scientific collaborators, academic institutions and their personnel;

 

The success of work to be conducted under the research and development collaboration between us and various contract development and manufacturing organizations (“CDMOs”);

 

Our ability to develop our therapies through early human testing;

 

Our ability to evaluate the financial returns on various commercialization approaches for our Product Candidates, such as a ‘go it-alone’ commercialization effort, out-licensing to third parties, or co-promotion agreements with strategic collaborators;

 

Our ability to oversee clinical trials for INM-755 in EB and building the requisite internal commercialization infrastructure to self-market the product to EB clinics;

 

Our ability to find a partnership early in the development process for INM-088 in glaucoma;

 

Our ability to explore our manufacturing technologies as processes which may confer certain benefits, either cost, yield, speed, or all of the above, when pursuing specific types of cannabinoids, and filing a provisional patent application for same;

 

Plans regarding our next steps, options, and targeted benefits of our manufacturing technologies;

 

Our IntegraSynTM or BayMedica derived products being bio-identical to the naturally occurring cannabinoids, and offering superior ease, control and quality of manufacturing when compared to alternative methods

 

Our ability to potentially earn revenue from our IntegraSynTM approach by (i) becoming a supplier of APIs to the pharmaceutical industry and/or (ii) providing pharmaceutical-grade ingredients to the non-pharmaceutical market;

 

Our plans to work closely with regulatory authorities and clinical experts in developing the clinical program for INM-755;

 

Our ability to successfully prosecute patent applications;

 

Our ability to complete formulation development and scale-up, conduct additional preclinical studies, and initiate and complete IND/CTA-enabling toxicology studies in calendar year 2023 for INM-088;

 

INM-088 being a once-a-day or twice-a-day eye drop medication that will compete with treatment modalities in the medicines category, and with the potential of INM-088 assisting in reducing the high rate of non-adherence with current glaucoma therapies;

 

Our belief that with a novel delivery system, the reduction of IOP and/or providing neuroprotection in glaucoma patients by topical (eye drop) application of cannabinoids will hold significant promise as a new therapy;

 

The potential for any of our patent applications to provide intellectual property protection for us;

 

Our ability to secure insurance coverage for shipping and storage of Product Candidates, and clinical trial insurance;

 

Our ability to expand our insurance coverage to include the commercial sale of Products and Product Candidates;

 

21

 

 

Developing patentable New Chemical Entities (“NCE”) which, if issued, will confer market exclusivity to us for the potential development into pharmaceutical Product Candidates, license, partner or sell to interested external parties;

 

Our ability to initiate discussions and conclude strategic partnerships to assist with development of certain programs;

 

Our ability to position ourselves to achieve value-driving, near term milestones for our Product Candidates with limited investment;

 

Our ability to execute our business strategy;

 

Critical accounting estimates;

 

Management’s assessment of future plans and operations;

 

The outlook of our business and the global economic and geopolitical conditions; and

 

The competitive environment in which we and our business units operate.

 

This list is not exhaustive of the factors that may affect our forward-looking statements. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations of this report. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated, or expected. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made and are based only on the information available to us at that time. Except as required by law, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

22

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

 

 

InMed Pharmaceuticals Inc.

 

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

 

Three Months Ended September 30, 2022

 

This discussion and analysis contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is subject to the safe harbor created by those sections. For more information, see “Cautionary Note Regarding Forward-Looking Statements.” When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we encourage you to review the risks and uncertainties described in “Risk Factors” in our Annual Report on Form 10-K, dated September 23, 2022. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this report. These forward-looking statements are made as of the date of this report, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law.

 

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated interim financial statements for the three months ended September 30, 2022, and the related notes thereto, which have been prepared in accordance with U.S. GAAP. Additionally, the following discussion and analysis should be read in conjunction with our audited consolidated financial statements included in our Form 10-K filing. Throughout this discussion, unless the context specifies or implies otherwise the terms “InMed,” “Company,” “we,” “us,” and “our” refer to InMed Pharmaceuticals Inc.

 

All dollar amounts stated herein are in U.S. dollars unless specified otherwise.

 

Overview

 

We are a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs (“Product Candidates”). Together with our subsidiary BayMedica, LLC, we also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors (“Products”). Our know-how includes traditional approaches such as chemical synthesis and biosynthesis, as well as a proprietary, integrated manufacturing approach called IntegraSynTM. We are dedicated to delivering new therapeutic alternatives to patients and consumers who may benefit from cannabinoid-based products. Our approach leverages on the several thousand years’ history of health benefits attributed to the Cannabis plant and brings this anecdotal information into the 21st century by applying tried, tested and true scientific approaches to establish non-plant-derived (synthetically manufactured), individual cannabinoid compounds as Product Candidates in important market segments including clinically proven, FDA-approved medicines and Products that are provided to wholesalers and end-product manufacturers. While our activities do not involve direct use of Cannabis nor extracts from the plant, we note that the U.S. Food and Drug Administration (“FDA”) has, to date, not approved any marketing application for Cannabis for the treatment of any disease or condition and has approved only one Cannabis-derived and three Cannabis-related drug products. Our ingredients are synthetically made and, therefore, we have no interaction with the Cannabis plant. We do not grow nor utilize Cannabis nor its extracts in any of our Products or Product Candidates; our current pharmaceutical drug Product Candidates are applied topically (not inhaled nor ingested); and, we do not utilize THC or CBD, the most common cannabinoid compounds that are typically extracted from the Cannabis plant, in any of our Products or Product Candidates. The active pharmaceutical ingredient (“API”) under development for our initial two drug candidates, INM-755 for Epidermolysis bullosa (“EB”) and INM-088 for glaucoma, is cannabinol (“CBN”). Additional uses of both INM-755 and INM-088 are being explored, as well as the application of novel cannabinoid analogs to treat diseases including but not limited to neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s.

 

23

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

We believe we are positioned to develop multiple pharmaceutical Product Candidates in diseases which may benefit from medicines based on rare cannabinoid compounds. Most currently approved cannabinoid therapies are based specifically on CBD and/or THC and are often delivered orally, which has limitations and drawbacks, such as side effects (including the intoxicating effects of THC). Currently, we intend to deliver our rare cannabinoid pharmaceutical drug candidates through various topical formulations (cream for dermatology, eye drops for ocular diseases) as a way of enabling treatment of the specific disease at the site of disease while seeking to minimize systemic exposure and any related unwanted systemic side effects, including any drug-drug interactions and any metabolism of the active pharmaceutical ingredient by the liver. The cannabinoid Products sold through our B2B raw material supply business are integrated into various product formats by the companies who then further commercializes such products. We plan to access rare cannabinoids via all non-extraction approaches, including chemical synthesis, biosynthesis and our proprietary integrated IntegraSynTM approach, thus negating any interaction with or exposure to the Cannabis plant. 

 

Since our acquisition of Biogen Sciences Inc., a privately held British Columbia pharmaceutical company focused on drug discovery and development of cannabinoids in 2014, our operations have focused on conducting research and development for our Product Candidates and for our integrated, biosynthesis-based manufacturing technology, establishing our intellectual property, organizing and staffing our Company, business planning and capital raising. On October 13, 2021, we acquired BayMedica, Inc., now named BayMedica, LLC (“BayMedica”). Upon closing of the transaction, BayMedica became a wholly-owned subsidiary of InMed. To date, we have funded our operations primarily through the issuance of common shares.

 

We have incurred significant operating losses since our inception and since the acquisition of Biogen Science Inc. and we expect to continue to incur significant operating losses for the foreseeable future. Our ability to generate product revenue, if ever, that is sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our drug candidates and/or the success of our manufacturing technologies. Our net loss was $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $97.0 million, which includes all losses since our inception in 1981. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and September 30, 2022 by approximately $68.1 million. We expect our expenses and operating losses will increase substantially over the next several years in connection with our ongoing activities as we:

 

continue to further advance the INM-755 program, our lead drug candidate for the treatment of EB;

 

continue to further advance the INM-088 program, our drug candidate for the treatment of glaucoma;

 

  investigate our Product Candidates for additional uses beyond the initial indications;

 

24

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

  pursue the discovery of drug targets based on proprietary cannabinoid analogs for other diseases with high unmet medical needs and the subsequent development of any resulting new Product Candidates;

 

  seek regulatory approvals for any Product Candidates that successfully complete clinical trials;

 

  scale-up our manufacturing processes and capabilities, or arrange for a third party to do so on our behalf;

 

  execute on business development activities, including but not limited to company mergers/acquisitions and acquisition or in-licensing of externally developed products and/or technologies;

 

 

maintain, expand, enforce, defend and protect our intellectual property;

 

 

continue to further advance the research and development of various manufacturing technologies;

 

  build internal infrastructure, including personnel, to meet our milestones; and

 

 

add operational, financial and management information systems and personnel, including personnel to support product development and potential future commercialization efforts and our operations as a public company.

 

As a result of these activities as well as our working capital requirements, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. We expect to finance our operations through product sales, the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our Products and Product Candidates or grant rights to external entities to develop and market our Product Candidates, even if we would otherwise prefer to develop and market such Products and Product Candidates ourselves.

 

Because of the numerous risks and uncertainties associated with drug development and commercial growth, we are unable to predict the timing or amount of increased expenses and working capital requirements or the timing of when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

 

25

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

Recent Developments

 

On September 13, 2022, we closed a $6.0 million private placement. Under the terms of the private placement, an aggregate of 691,245 common shares, or common share equivalents, and investment options to purchase up to an aggregate of 1,382,490 common shares, at an effective purchase price of $8.68 per common share and associated investment options. The warrants have an exercise price of $8.44 per share, are exercisable immediately and have a term of seven years. After deducting the placement agent fees, we received net cash proceeds of approximately $5.4 million.

 

Components of Results of Operations

 

Revenue

 

Our revenue consists of manufacturing and distribution sales of bulk rare cannabinoid Products, which are generally recognized at a point in time. The Company recognizes revenue when control over the products have been transferred to the customer and the Company has a present right to payment.

 

Cost of Sales

 

Cost of sales consist primarily of the purchase price of goods and cost of services rendered, freight costs, warehousing costs, and purchasing costs. Cost of sales also includes production and labor costs for our manufacturing business.

 

Operating Expenses

 

Research and Development and Patent Expenses

 

Research and development and patent expenses represent costs incurred by us for the discovery, development, and manufacture of our Products and Product Candidates and include:

 

  external research and development expenses incurred under agreements with contract research organizations, or “CROs”, contract development and manufacturing organization, or “CDMOs”, and consultants;

 

salaries, payroll taxes, employee benefits expenses for individuals involved in research and development efforts;

 

research supplies; and

 

legal and patent office fees related to patent and intellectual property matters.

 

We expense research and development costs as incurred. We recognize expenses for certain development activities, such as preclinical studies and manufacturing, based on an evaluation of the progress to completion of specific tasks using data or other information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of expenses incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. These amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.

 

26

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

External costs represent a significant portion of our research and development expenses, which we track on a program-by-program basis following the nomination of a development candidate. Our internal research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock-based compensation expense. We do not track our internal research and development expenses on a program-by-program basis as the resources are deployed across multiple projects.

 

The successful development of our Products and Product Candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the remainder of the development of our Product Candidates or to develop and commercialize additional Products. We are also unable to predict when, if ever, material net cash inflows will commence from our Product Candidates, if approved. This is due to the numerous risks and uncertainties associated with development, including the uncertainty related to:

 

the timing and progress of preclinical and clinical development activities;
  
 

the number and scope of preclinical and clinical programs we decide to pursue;

 

  our ability to raise additional funds necessary to complete preclinical and clinical development and commercialization of our Product Candidates, to further advance the development of our manufacturing technologies, and to develop and commercialize additional Products, if any;

 

  our ability to maintain our current research and development programs and to establish new ones;

 

 

our ability to establish sales, licensing or collaboration arrangements;

 

  the progress of the development efforts of parties with whom we may enter into collaboration arrangements;

  the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;

 

  the receipt and related terms of regulatory approvals from applicable regulatory authorities;

 

  the availability of materials for use in production of our Products and Product Candidates;

 

our ability to secure manufacturing supply through relationships with third parties or establish and operate a manufacturing facility;

 

our ability to consistently manufacture our Product Candidates in quantities sufficient for use in clinical trials;

 

our ability to obtain and maintain intellectual property protection and regulatory exclusivity, both in the United States and internationally;

 

our ability to maintain, enforce, defend and protect our rights in our intellectual property portfolio;

 

the commercialization of our Product Candidates, if and when approved, and of new Products;

 

our ability to obtain and maintain third-party payor coverage and adequate reimbursement for our Product Candidates, if approved;

 

the acceptance of our Product Candidates, if approved, by patients, the medical community and third-party payors;

 

competition with other products; and

 

a continued acceptable safety profile of our Product Candidates following receipt of any regulatory approvals.

 

A change in the outcome of any of these variables with respect to the development of any of our Products or Product Candidates would significantly change the costs and timing associated with the development of those Products or Product Candidates.

 

Research and development activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy, which includes advancing our drug candidates and our manufacturing technologies into and through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, ultimately seeking regulatory approvals for our drug candidates that successfully complete clinical trials, and further developing selected BayMedica activities. In addition, drug candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, although we expect our research and development expenses to increase as our drug candidates advance into later stages of clinical development, we do not believe that it is possible, at this time, to accurately project total program-specific expenses through to commercialization. There are numerous factors associated with the successful commercialization of any of our Product Candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.  

 

27

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

General and Administrative Expenses

 

General and administrative expenses consist of personnel-related costs, including salaries, benefits and stock-based compensation expense, for our personnel in executive, finance and accounting, human resources, business operations and other administrative functions, investor relations activities, legal fees related to corporate matters, fees paid for accounting and tax services, consulting fees and facility-related costs.

 

We expect our general and administrative expenses will increase for the foreseeable future to support our expanded infrastructure, operating as a public company and increased costs of expanding our operations. These increases will likely include increased expenses related to accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.  

 

Amortization and Depreciation

 

Intangible assets are comprised of intellectual property that we acquired in 2014 and 2015 and trade secrets, product formulation knowledge, patents that we acquired in October 2021. The acquired intellectual property and patents are amortized on a straight-line basis based on their estimated useful lives. Equipment and leasehold improvements are depreciated using the straight-line method based on their estimated useful lives.  

 

Impairment of Long-Lived Assets

 

We assess the recoverability of our long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or assets. If carrying value exceeds the sum of undiscounted cash flows, we then determine the fair value of the underlying asset. Any impairment to be recognized is measured as the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell.  

 

Share-based Payments

 

Share-based payments is the stock-based compensation expense related to our granting of stock options to employees and others. The fair value, at the grant date, of equity-settled share awards is charged to our loss over the period for which the benefits of employees and others providing similar services are expected to be received. The vesting components of graded vesting employee awards are measured separately and expensed over the related tranche’s vesting period. The amount recognized as an expense is adjusted to reflect the number of share options expected to vest. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers the exercise price, current market price of the underlying shares, expected life of the award, risk-free interest rate, expected volatility and the dividend yield.  

 

Other Income

 

Other income consists primarily of interest income earned on our cash, cash equivalents and short-term investments.  

 

Results of Operations

 

As of the closing of the BayMedica acquisition, the Company aligned into two operating and reportable segments, InMed Pharmaceuticals (the “InMed” segment) and BayMedica (the “BayMedica” segment).

 

Comparison of the three months ended September 30, 2022 and 2021 for InMed Segment

 

  

Three Months Ended

September 30,

         
   2022   2021   Change   % Change 
   (in thousands)         
Operating expenses:                
Research and development and patents   1,080    1,491    (411)   -28%
General and administrative   1,093    1,373    (280)   -22%
Amortization and depreciation   26    29    (3)   -10%
Total operating expenses   2,199    2,893    (694)   -24%
Interest and other income   28    5    23    460%
Foreign exchange loss   (97)   (85)   (12)   14%
Net loss  $(2,268)  $(2,973)  $705    -24%

 

28

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

Research and Development and Patents Expenses

 

Research and development and patents expenses decreased by $0.4 million in our InMed segment, or 28%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. The decrease in research and development and patents expenses was primarily due to decreased activities related to the INM-755 Phase 2 clinical trials.

 

General and administrative expenses

 

General and administrative expenses decreased by $0.3 million in our InMed segment, or 20%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. The decrease results primarily from a combination of changes including lower personnel expenses, legal fees, investor relation expenses and accounting fees, partially offset by higher consulting fees.

 

Foreign exchange loss

 

Foreign exchange loss increased by less than $0.1 million in our InMed segment, or 14%, for the three months ended September 30, 2022, compared to the three months ended September 30, 2021, as a consequence of holding non-US denominated assets and liabilities combined with fluctuations in foreign exchange rates.

 

Comparison of the three months ended September 30, 2022 and 2021 for BayMedica Segment

 

  

Three Months Ended

September 30,

        
   2022   2021   Change   % Change
   (in thousands)        
Sales  $321   $-   $321   nm
Cost of sales   235    -    235   nm
Inventory write-down   577    -    577   nm
Gross loss   (491)   -    (491)  nm
                   
Operating expenses:                  
Research and development and patents   299    -    299   nm
General and administrative   467    -    467   nm
Amortization and depreciation   23    -    23   nm
Total operating expenses   789    -    789   nm
Interest and other income   45    -    45   nm
Tax expense   (7)   -    (7)  nm
Net loss  $(1,242)  $-   $(1,242)  nm

 

Sales

 

We realized sales of $0.3 million in our BayMedica segment for the three months ended September 30, 2022, the result of manufacturing and distribution sales of bulk rare cannabinoid Products following the acquisition of BayMedica in October 2021. As the three months ended September 30, 2021 pre-dated the acquisition of BayMedica, there are no comparable revenues in the 2021 period. As management has made the decision to refocus on our core business in the pharmaceutical drug development area and reduce our efforts in BayMedica’s commercial business, we expect to sell inventory on-hand as of September 30, 2022 over the next 15 months. BayMedica will continue to evaluate opportunities for potential structured supply arrangements and collaborations and will consider other potential strategic alternatives for the commercial business.

 

29

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

Cost of Sales

 

We realized cost of goods sold of $0.2 million in our BayMedica segment for the three months ended September 30, 2022, with no comparable expenses in 2021.

 

Inventory Write-Down

 

The write-down of inventories to net realizable value was $0.6 million in our BayMedica segment for the three months ended September 30, 2022, with no comparable expenses in 2021. Contributing factors to the decrease in net realizable value included lower demand and downward pricing pressure.

 

Gross Loss

 

We realized gross loss of $0.5 million in our BayMedica segment for the three months ended September 30, 2022, with no comparable loss in 2021.

 

Research and Development and Patents Expenses

 

Research and development and patents expenses were $0.3 million in our BayMedica segment for the three months ended September 30, 2022. The increase in research and development and patents expenses was due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

 

General and administrative expenses

 

General and administrative expenses were $0.5 million in our BayMedica segment for the three months ended September 30, 2022. The increase is due to the inclusion of BayMedica operating results following the acquisition date. There were no comparable expenses in 2021.

 

Liquidity and Capital Resources

 

Since our inception, we have only generated limited revenue from Product sales, no sales from any other sources and have incurred significant operating losses and negative cash flows from our operations. We have only commenced commercial sales with the acquisition of BayMedica and not yet commercialized any of our Product Candidates and we do not expect to generate revenue from sales of any Product Candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of common shares.

 

As of September 30, 2022, we had cash and cash equivalents of $9.4 million.

 

The following table summarizes our cash flows for each of the periods presented:

 

(in thousands)  Three Months
Ended
September 30,
2022
   Three Months
Ended
September 30,
2021
 
Net cash used in operating activities  $(2,256)  $(2,654)
Net cash used in investing activities   -    (250)
Net cash provided by financing activities   5,430    10,885 
Net increase in cash and cash equivalents  $3,174   $7,981 

 

30

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

Operating Activities

 

During the three months ended September 30, 2022, we used cash in operating activities of $2.3 million, primarily resulting from our net loss of $3.5 million combined with $0.5 million used in changes in our non-cash working capital, partially offset by non-cash share-based compensation expenses and inventory write-down.

 

During the three months ended September 30, 2021, we used cash in operating activities of $2.7 million, primarily resulting from our net loss of $3.0 million combined with $0.2 million used in changes in our non-cash working capital, partially offset by non-cash share-based compensation expenses. 

 

Investing Activities

 

During the three months ended September 30, 2022, there were no investing activities.

 

During the three months ended September 30, 2021, we used cash in investing activities of $0.3 million, resulting from a pre-acquisition short-term loan to BayMedica.

 

Financing Activities

 

During the three months ended September 30, 2022, cash provided by financing activities of $5.4 million consisted of $6.0 million of gross proceeds from a private placement of our common shares, offset by total transaction costs of $0.6 million.

 

During the three months ended September 30, 2021, cash provided by financing activities of $10.9 million consisted of $12.0 million of gross proceeds from a private placement of our common shares, offset by transaction costs of $1.1 million.

 

Funding Requirements

 

We expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we continue the research and development of and the clinical trials for our Product Candidates. In addition, we expect to incur additional costs associated with operating as a US-listed public company and associated with any required investment into BayMedica’s R&D efforts targeting cannabinoid analogs. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future.

 

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

 

Through September 30, 2022, we have funded our operations primarily with proceeds from the sale of common stock. We have incurred recurring losses and negative cash flows from operations since its inception, including net losses of $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. In addition, we have an accumulated deficit of $97.0 million as of September 30, 2022. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and September 30, 2022 by approximately $68.1 million and we expect to continue to generate operating losses for the foreseeable future.

 

As of the issuance date of the condensed consolidated interim financial statements, we expect our cash and cash equivalents of $9.4 million as of September 30, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. Our future viability is dependent on our ability to raise additional capital to finance our operations. In addition, there are a number of uncertainties in estimating our operating expenses and capital expenditure requirements including the impact of potential acquisitions.

 

31

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

 

We expect to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our existing stockholders.

 

Our funding requirements and timing and amount of our operating expenditures will depend largely on:

 

  the progress, costs and results of our Phase 2 clinical trial for INM-755;

 

  the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our Product Candidates;

 

 

the scope, progress, results and costs of development of our manufacturing technologies; 

     
  the number of and development requirements for other Products and Product Candidates that we pursue;

 

  the costs, timing and outcome of regulatory review of our Product Candidates;
     
 

our ability to enter into contract manufacturing arrangements for supply of materials and manufacture of our Products and Product Candidates and the terms of such arrangements; 

     
  the impact of any acquired, or in-licensed, externally developed product(s) and/or technologies;

 

  our ability to establish and maintain strategic collaborations, licensing or other arrangements, including sales arrangements, and the financial terms of such arrangements;

 

  the sales, costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our Products and for Product Candidates for which we may receive marketing approval;

 

  the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property- related claims;

 

  expansion costs of our operational, financial and management systems and increases to our personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a dual listed company; and

 

  the costs to obtain, maintain, expand and protect our intellectual property portfolio.

 

32

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

A change in the outcome of any of these, or other variables with respect to the development of any of our Products and Product Candidates, could significantly change the costs and timing associated with their development. We will need to continue to rely on additional financing to achieve our business objectives.

 

In addition to the variables described above, if and when any of our Product Candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time.

 

Until such time, if ever, as we can generate substantial revenues from either our Products or Product Candidates, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the future sale of equity securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common shareholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts, and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements or other strategic transactions in the future, we may have to relinquish valuable rights to our technologies, future revenue streams, Products or Product Candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts or grant rights to develop and market Products or Product Candidates that we would otherwise prefer to develop and market ourselves.

 

Off-Balance Sheet Arrangements

 

During the periods presented we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

We periodically review our financial reporting and disclosure practices and accounting policies to ensure that they provide accurate and transparent information relative to the current economic and business environment. As part of this process, we have reviewed our selection, application and communication of critical accounting policies and financial disclosures. Management has discussed the development and selection of the critical accounting policies with the Audit Committee of the Board of Directors and the Audit Committee has reviewed the disclosure relating to critical accounting policies in this Management’s Discussion and Analysis.

 

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated interim financial statements included as part of this report, which have been prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated interim financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the revenue and expenses incurred during the reported periods. We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Detailed information about our critical accounting policies and estimates is set forth in Part II, Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2022. There have been no significant changes to these policies during the three months ended September 30, 2022.

 

33

 

 

InMed Pharmaceuticals Inc.

MANAGEMENT’S DISCUSSION AND ANALYSIS

Three months ended September 30, 2022

 

 

Going Concern

 

Through September 30, 2022, we have funded our operations primarily with proceeds from the sale of common shares. We have incurred recurring losses and negative cash flows from operations since our inception, including net losses of $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. In addition, we have an accumulated deficit of $97.0 million as of September 30, 2022. Our accumulated deficit increased between 2014, when we began focusing on the development of cannabinoid-derived pharmaceuticals following the acquisition of Biogen Science Inc., and June 30, 2022 by approximately $68.1 million and we expect to continue to generate operating losses for the foreseeable future.

 

As of the issuance date of the condensed consolidated interim financial statements, we expect our cash and cash equivalents of $9.4 million as of September 30, 2022 will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expense. Our future viability is dependent on our ability to raise additional capital to finance our operations. In addition, there are a number of uncertainties in estimating our operating expenses and capital expenditure requirements including the impact of potential acquisitions.

 

As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated interim financial statements are issued.

 

We expect to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our existing shareholders.

 

34

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. As of September 30, 2022, the Chief Executive Officer and the Chief Financial Officer, with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon the evaluation, they have concluded that, as of September 30, 2022, our disclosure controls and procedures were not effective at a reasonable assurance level due to a material weakness that existed in our internal controls over financial reporting, primarily the result of inadequate resources required to respond to financial reporting matters other than in the normal course of business, as disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

 

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fiscal quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Remediation

 

We began implementing a remediation plan to address the previously reported material weakness in internal control over financial reporting, described in Part II, Item 9A, “Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. Remediation measures include retaining the services of outside consultants and establishing additional review procedures over the accounting for complex and non-routine transactions. The material weakness will not be considered remediated, until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We expect that the remediation of this material weakness will be completed prior to the end of fiscal year 2023. Notwithstanding the material weakness, we believe the financial statements in this report fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with U.S. GAAP.

 

35

 

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS.

 

We are not involved in any material active legal actions. However, from time to time, we may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of our business.

 

ITEM 1A. RISK FACTORS.

 

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. For a discussion of our potential risks and uncertainties, please review the risks and uncertainties described in “Risk Factors” in our Form 10-K dated September 23, 2022.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURE.

 

None

 

ITEM 5. OTHER INFORMATION.

 

None. 

 

ITEM 6. EXHIBITS.

 

Exhibits

 

The following exhibits are filed as part of this report:

  

Exhibit
Number
  Description
31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended
     
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended
     
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

36

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
  (Registrant)
   
Dated: November 14, 2022 By: /s/ Brenda Edwards
    Interim Chief Financial Officer

 

 

37

 

 

Unlimited Unlimited 4.06 6.17 481902 865619 4.06 6.17 481902 865619 false --06-30 Q1 2023 0001728328 0001728328 2022-07-01 2022-09-30 0001728328 2022-11-14 0001728328 2022-09-30 0001728328 2022-06-30 0001728328 2021-07-01 2022-06-30 0001728328 2021-07-01 2021-09-30 0001728328 us-gaap:CommonStockMember 2021-06-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001728328 us-gaap:RetainedEarningsMember 2021-06-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001728328 2021-06-30 0001728328 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001728328 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001728328 us-gaap:CommonStockMember 2021-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001728328 us-gaap:RetainedEarningsMember 2021-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001728328 2021-09-30 0001728328 us-gaap:CommonStockMember 2022-06-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001728328 us-gaap:RetainedEarningsMember 2022-06-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001728328 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001728328 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001728328 us-gaap:CommonStockMember 2022-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001728328 us-gaap:RetainedEarningsMember 2022-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001728328 inm:CustomerOneMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0001728328 inm:RightOfUseAssetMember 2022-09-30 0001728328 inm:RightOfUseAssetMember 2022-06-30 0001728328 us-gaap:EquipmentMember 2022-09-30 0001728328 us-gaap:EquipmentMember 2022-06-30 0001728328 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001728328 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001728328 us-gaap:IntellectualPropertyMember 2022-07-01 2022-09-30 0001728328 us-gaap:PatentsMember 2022-07-01 2022-09-30 0001728328 2021-09-01 2021-09-13 0001728328 inm:BayMedicaAgreementMember 2022-09-30 0001728328 2022-09-01 2022-09-13 0001728328 2022-09-13 0001728328 us-gaap:WarrantMember 2022-09-13 0001728328 us-gaap:WarrantMember 2022-09-01 2022-09-13 0001728328 inm:SharesIssuedMember 2022-07-01 2022-09-30 0001728328 inm:SharesIssuedMember 2022-09-30 0001728328 inm:PrivatePlacementPrefundedWarrantsMember 2022-07-01 2022-09-30 0001728328 inm:PrivatePlacementPrefundedWarrantsMember 2022-09-30 0001728328 inm:GrossProceedsMember 2022-07-01 2022-09-30 0001728328 inm:AllocatedToAdditionalPaidinCapitalMember 2022-07-01 2022-09-30 0001728328 inm:ShareIssuanceCostsMember 2022-07-01 2022-09-30 0001728328 inm:SharePurchaseWarrantsMember 2022-06-30 0001728328 inm:SharePurchaseWarrantsMember 2022-09-30 0001728328 inm:AgentsWarrantsMember 2022-06-30 0001728328 inm:AgentsWarrantsMember 2022-09-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-06-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-07-01 2022-09-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-09-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-06-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-07-01 2022-09-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-09-30 0001728328 2017-03-01 2017-03-24 0001728328 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001728328 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001728328 srt:ScenarioForecastMember 2024-04-01 2024-04-30 0001728328 srt:ScenarioForecastMember 2024-08-01 2024-08-31 0001728328 inm:InMedMember 2022-07-01 2022-09-30 0001728328 inm:BayMedicaMember 2022-07-01 2022-09-30 0001728328 inm:InMedMember 2021-07-01 2021-09-30 0001728328 inm:BayMedicaMember 2021-07-01 2021-09-30 0001728328 inm:InMedMember 2022-09-30 0001728328 inm:BayMedicaMember 2022-09-30 0001728328 inm:InMedMember 2021-09-30 0001728328 inm:BayMedicaMember 2021-09-30 0001728328 2021-07-02 0001728328 2021-10-01 2022-09-30 0001728328 inm:CanadianDollarMember 2022-07-01 2022-09-30 0001728328 inm:CanadianDollarMember 2021-07-01 2021-09-30 0001728328 inm:BayMedicaAgreementMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-13 0001728328 us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001728328 us-gaap:SubsequentEventMember 2022-10-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CAD xbrli:shares iso4217:CAD
EX-31.1 2 f10q0922ex31-1_inmedpharma.htm CERTIFICATION

Exhibit 31.1

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Eric A. Adams, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 14, 2022

 

  /s/ Eric A. Adams
  Name:  Eric A. Adams
  Title: President and Chief Executive Officer

 

EX-31.2 3 f10q0922ex31-2_inmedpharma.htm CERTIFICATION

Exhibit 31.2

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Brenda Edwards, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of InMed Pharmaceuticals Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 14, 2022

 

  /s/ Brenda Edwards
  Name:  Brenda Edwards
  Title: Interim Chief Financial Officer

 

EX-32.1 4 f10q0922ex32-1_inmedpharma.htm CERTIFICATION

Exhibit 32.1

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Eric A. Adams, the President and Chief Executive Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:

 

1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 14, 2022

 

  /s/ Eric A. Adams
  Name:  Eric A. Adams
  Title: President and Chief Executive Officer

 

 

 

EX-32.2 5 f10q0922ex32-2_inmedpharma.htm CERTIFICATION

Exhibit 32.2

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Brenda Edwards, the Chief Financial Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:

 

1.The Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 14, 2022

 

  /s/ Brenda Edwards
  Name:  Brenda Edwards
  Title: Interim Chief Financial Officer

 

EX-101.SCH 6 inm-20220930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Interim Statements of Shareholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Corporate Information and Continuing Operations link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Customer Concentration link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Property, Equipment and Rou Assets, Net link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Share Capital and Reserves link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Share-Based Payments link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Lease Obligations link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Basic and Diluted Loss per Share link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Non-Cash Transactions link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Financial Risk Management link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property, Equipment and Rou Assets, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Share Capital and Reserves (Tables) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Lease Obligations (Tables) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Basic and Diluted Loss per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Corporate Information and Continuing Operations (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Customer Concentration (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Inventories (Details) - Schedule of inventories link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Property, Equipment and Rou Assets, Net (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Share Capital and Reserves (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Share Capital and Reserves (Details) - Schedule of Private Placement Offering link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in preferred investment options link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents' investment options link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Share-Based Payments (Details) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Share-Based Payments (Details) - Schedule of options activity link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Lease Obligations (Details) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Segment Information (Details) - Schedule of reportable segments link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Non-Cash Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Financial Risk Management (Details) link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 inm-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 inm-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 inm-20220930_lab.xml XBRL LABEL FILE EX-101.PRE 10 inm-20220930_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 12 fin_001.jpg GRAPHIC begin 644 fin_001.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information - shares
3 Months Ended
Sep. 30, 2022
Nov. 14, 2022
Document Information Line Items    
Entity Registrant Name INMED PHARMACEUTICALS INC.  
Trading Symbol INM  
Document Type 10-Q  
Current Fiscal Year End Date --06-30  
Entity Common Stock, Shares Outstanding   936,761
Amendment Flag false  
Entity Central Index Key 0001728328  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2022  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-39685  
Entity Incorporation, State or Country Code A1  
Entity Tax Identification Number 98-1428279  
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street  
Entity Address, Address Line Two Vancouver  
Entity Address, City or Town B.C  
Entity Address, Country CA  
Entity Address, Postal Zip Code V6C 1B4  
City Area Code (604)  
Local Phone Number 669-7207  
Title of 12(b) Security Common Shares, no par value  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Current    
Cash and cash equivalents $ 9,350,427 $ 6,176,866
Short-term investments 42,125 44,804
Accounts receivable 15,169 88,027
Inventories 1,778,523 2,490,854
Prepaids and other assets 356,665 797,225
Total current assets 11,542,909 9,597,776
Non-Current    
Property, equipment and ROU assets, net 802,369 904,252
Intangible assets, net 2,067,922 2,108,915
Other assets 171,130 176,637
Total Assets 14,584,330 12,787,580
Current    
Accounts payable and accrued liabilities 2,362,190 2,415,265
Current portion of lease obligations 404,163 404,276
Deferred revenue 15,700
Acquisition consideration payable 500,000 500,000
Total current liabilities 3,282,053 3,319,541
Non-current    
Lease obligations 294,337 389,498
Total Liabilities 3,576,390 3,709,039
Shareholders’ Equity    
Common shares, no par value, unlimited authorized shares:908,766 (June 30, 2022 - 650,667) issued and outstanding 72,671,392 70,718,461
Additional paid-in capital 35,170,766 31,684,098
Accumulated deficit (96,962,787) (93,452,587)
Accumulated other comprehensive income 128,569 128,569
Total Shareholders’ Equity 11,007,940 9,078,541
Total Liabilities and Shareholders’ Equity $ 14,584,330 $ 12,787,580
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Statement of Financial Position [Abstract]    
Common stock par value (in Dollars per share)
Common stock, shares authorized Unlimited Unlimited
Common stock, shares issued 908,766 650,667
Common stock, shares outstanding 908,766 650,667
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Sales $ 320,788
Cost of sales 235,034
Inventory write-down 576,772  
Gross loss (491,018)
Operating Expenses    
Research and development and patents 1,378,653 1,491,252
General and administrative 1,560,477 1,372,867
Amortization and depreciation 49,048 28,532
Total operating expenses 2,988,178 2,892,651
Other Income (Expense)    
Interest and other income 72,587 5,148
Foreign exchange loss (96,791) (84,112)
Loss before income taxes (3,503,400) (2,971,615)
Tax expense (6,800)
Net loss for the period $ (3,510,200) $ (2,971,615)
Net loss per share for the period    
Net loss per share, Basic (in Dollars per share) $ (4.06) $ (6.17)
Weighted average outstanding common shares    
Weighted average outstanding common shares, Basic (in Shares) 865,619 481,902
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net loss per share, Diluted $ (4.06) $ (6.17)
Weighted average outstanding common shares, Diluted 865,619 481,902
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Statements of Shareholders’ Equity (Unaudited) - USD ($)
Common Shares
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Total
Balance at Jun. 30, 2021 $ 60,587,417 $ 21,513,051 $ (74,852,470) $ 128,569 $ 7,376,567
Balance (in Shares) at Jun. 30, 2021 322,028        
Private placement $ 1,459,051 10,540,635 11,999,686
Private placement (in Shares) 35,600        
Share issuance costs $ (247,336) (1,786,831) (2,034,167)
Agents’ warrants 739,920 739,920
Exercise of pre-funded warrants $ 1,887,592 (1,887,453) 139
Exercise of pre-funded warrants (in Shares) 55,453        
Loss for the period (2,971,615) (2,971,615)
Share-based compensation 111,142 111,142
Balance at Sep. 30, 2021 $ 63,686,724 29,230,464 (77,824,085) 128,569 15,221,672
Balance (in Shares) at Sep. 30, 2021 413,081        
Balance at Jun. 30, 2022 $ 70,718,461 31,684,098 (93,452,587) 128,569 9,078,541
Balance (in Shares) at Jun. 30, 2022 650,667        
Private placement $ 410,376 5,589,570 5,999,946
Private placement (in Shares) 90,000        
Share issuance costs $ (77,242) (1,052,101) (1,129,343)
Agents’ investment options 451,897 451,897
Exercise of pre-funded warrants $ 1,619,797 (1,619,378) 419
Exercise of pre-funded warrants (in Shares) 168,099        
Loss for the period (3,510,200) (3,510,200)
Share-based compensation 116,680 116,680
Balance at Sep. 30, 2022 $ 72,671,392 $ 35,170,766 $ (96,962,787) $ 128,569 $ 11,007,940
Balance (in Shares) at Sep. 30, 2022 908,766        
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating Activities    
Net loss for the period $ (3,510,200) $ (2,971,615)
Items not requiring cash:    
Amortization and depreciation 49,048 28,532
Share-based compensation 116,680 111,142
Amortization of right-of-use assets 99,460 25,906
Interest income received on short-term investments (120) (23)
Unrealized foreign exchange loss 2,796 1,262
Inventory write-down 576,772
Payments on lease obligations (100,903) (17,411)
Changes in non-cash working capital:    
Inventories 135,559
Prepaids and other assets 440,560 634,410
Other non-current assets 5,507 6,030
Accounts receivable 72,858 (2,923)
Accounts payable and accrued liabilities (159,260) (469,227)
Deferred revenue 15,700
Total cash used in operating activities (2,255,543) (2,653,917)
Investing Activities    
Short-term loan (250,000)
Total cash used in investing activities (250,000)
Financing Activities    
Shares issued for cash 6,000,365 11,999,825
Share issuance costs (571,261) (1,115,129)
Total cash provided by financing activities 5,429,104 10,884,696
Increase (decrease) in cash during the period 3,173,561 7,980,779
Cash and cash equivalents beginning of the period 6,176,866 7,363,126
Cash and cash equivalents end of the period $ 9,350,427 $ 15,343,905
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Corporate Information and Continuing Operations
3 Months Ended
Sep. 30, 2022
Corporate Information and Continuing Operations [Abstract]  
CORPORATE INFORMATION AND CONTINUING OPERATIONS
1.CORPORATE INFORMATION AND CONTINUING OPERATIONS

 

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the Business Corporations Act of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

 

The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s corporate office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.

 

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

 

Through September 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $97.0 million as of September 30, 2022 (June 30, 2022 - $93.5 million). The Company expects to continue to generate operating losses for the foreseeable future.

 

As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash and cash equivalents of $9.4 million as of September 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

 

The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.

 

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies
3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
2.SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2022.

 

These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2022.

 

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “$” and “US$” are to United States (“U.S.”) dollars and references to “C$” are to Canadian dollars.

 

Use of Estimates

 

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.

 

COVID-19 Impacts

 

The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.

 

Recent Accounting Pronouncements Not Yet Adopted

 

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Customer Concentration
3 Months Ended
Sep. 30, 2022
Risks and Uncertainties [Abstract]  
CUSTOMER CONCENTRATION
3.CUSTOMER CONCENTRATION

 

The Company had three customers during the three months ended September 30, 2022, which individually generated 10% or more of the Company’s sales. These customers accounted for 78% of the Company’s sales for the three months ended September 30, 2022. There were no outstanding amounts receivable from these customers as at September 30, 2022.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
3 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
INVENTORIES
4.INVENTORIES

 

Inventories consisted of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Raw materials   292,577    292,577 
Work in process   1,210,261    1,724,851 
Finished goods   275,685    473,426 
Inventories   1,778,523    2,490,854 

 

During the three months ended September 30, 2022, inventory expensed to cost of goods sold was $235,034 (2021 - $Nil).

 

During the three months ended September 30, 2022, the write-down of inventories to net realizable value was $576,772 (2021 - $Nil). Contributing factors to the decrease in net realizable value included lower demand and downward pricing pressure.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property, Equipment and Rou Assets, Net
3 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY, EQUIPMENT AND ROU ASSETS, NET
5.PROPERTY, EQUIPMENT AND ROU ASSETS, NET

 

Property, equipment and ROU assets consisted of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Right-of-Use Assets (leases)   1,167,436    1,167,436 
Equipment   212,877    212,877 
Leasehold Improvements   40,409    40,409 
Property and equipment   1,420,722    1,420,722 
Less: accumulated depreciation and amortization   (618,353)   (516,470)
Property, equipment and ROU assets, net   802,369    904,252 

 

Depreciation expense on property, equipment and leasehold improvements for the three months ended September 30, 2022, was $8,055 (2021 - $4,217). Amortization expense related to the right-of-use assets for the three months ended September 30, 2022, was $90,244 (2021 - $21,343) and was recorded in general and administrative expenses.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets
3 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS
6.INTANGIBLE ASSETS

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Intellectual property   1,736,420    1,736,420 
Patents   1,191,000    1,191,000 
Intangible assets   2,927,420    2,927,420 
Less: accumulated depreciation   (859,498)   (818,505)
Intangible assets, net   2,067,922    2,108,915 

 

Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.

 

Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years.

 

As at September 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.

 

Amortization expense on intangible assets for the three months ended September 30, 2022 was $40,993 (2021 - $24,315). The Company expects amortization expense to be incurred over the next five years as follows:

 

   $ 
     
2023   155,778 
2024   155,778 
2025   155,778 
2026   155,778 
2027   155,778 
    778,890 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities
3 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
7.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities consist of the following:

 

   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Trade payables   1,096,212    1,166,068 
Accrued research and development expenses   956,429    839,638 
Employee compensation, benefits and related accruals   249,593    139,120 
Accrued general and administrative expenses   59,956    270,439 
Accounts payable and accrued liabilities   2,362,190    2,415,265 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves
3 Months Ended
Sep. 30, 2022
Share Capital And Reserves [Abstract]  
SHARE CAPITAL AND RESERVES
8.SHARE CAPITAL AND RESERVES

 

a)Authorized

 

As at September 30, 2022, the Company’s authorized share structure consisted of: (i) an unlimited number of common shares without par value; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at September 30, 2022 and June 30, 2022.

 

The Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of common shares.

 

b)Common Shares

 

During the three months ended September 30, 2022, the Company completed the following:

 

September 2022 Private Placement Offering:

 

Transaction Description  Number   Issue Price   Total 
Shares Issued   90,000   $8.680   $781,200 
Pre-funded Warrants Issued   601,245   $8.6799    5,218,746 
Gross Proceeds            $5,999,946 
Allocated to Additional Paid-in Capital             (5,589,570)
             $410,376 
Share Issuance Costs            $(77,242)

 

On September 13, 2022, the Company closed a private placement of its common shares and issued an aggregate of 90,000 common shares and 601,245 pre-funded warrants, for gross proceeds of $5,999,946. The pre-funded warrants were determined to be common stock equivalents. Each common share and each pre-funded warrant were sold in the offering with an investment option to purchase a common share. Transaction costs were allocated proportionally between common shares and investment options with $77,242 allocated to common shares and the balance of $1,052,101 allocated to additional paid-in capital and recorded as a component of shareholders’ equity in the consolidated balance sheet. As at September 30, 2022, there were 601,245 pre-funded warrants outstanding.

 

c)Share Purchase Warrants

 

The following is a summary of changes in share purchase warrants from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   244,767   $41.99         - 
Cancelled   (179,231)  $18.50    - 
Balance as at September 30, 2022   65,536   $106.23    - 

 

The total intrinsic value of warrants exercised during the three months ended September 30, 2022 was $Nil (2021 - $Nil).

 

d)Agents’ Warrants

 

The following is a summary of changes in agents’ warrants from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   12,109   $92.91         - 
Balance as at September 30, 2022   12,109   $92.91    - 

 

e)Preferred Investment Options

 

On September 13, 2022, 1,382,490 preferred investment options were issued with an exercise price of $8.44 per share, were immediately exercisable upon issuance, and expire 7 years following the date of issuance.

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   233,100   $18.50           - 
Granted   1,382,490   $8.44    - 
Cancelled   (233,100)  $18.50    - 
Balance as at September 30, 2022   1,382,490   $8.44    - 

 

f)Agents’ Investment Options

 

On September 13, 2022, 44,931 preferred investment options were issued for services with an exercise price of $10.85 per share, were immediately exercisable upon issuance, and expire approximately 7 years following the date of issuance.

 

   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   15,152   $26.81           - 
Granted   44,931   $10.85    - 
Balance as at September 30, 2022   60,083   $14.88    - 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments
3 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED PAYMENTS
9.SHARE-BASED PAYMENTS

 

a)Option Plan Details

 

On March 24, 2017, and as amended on November 20, 2020, the Company’s shareholders approved: (i) the adoption of a new stock option plan (the “Plan”) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company’s previous stock option plan.

 

As at September 30, 2022, there were 20,300 (June 30, 2022 – 18,163) options available for future allocation pursuant to SEC rules and 20% of the issued and outstanding shares according to the terms of the Plan. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.

 

Stock options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock options are granted with United States dollar exercise prices.

 

The following is a summary of changes in outstanding options from July 1, 2022 to September 30, 2022:

 

   Number   Weighted Average
Exercise Price
$
 
Balance as at June 30, 2022   55,603    128.59 
Granted   560    9.75 
Expired/Forfeited   (2,697)   46.62 
Balance as at September 30, 2022   53,466    124.74 
           
September 30, 2022:          
Vested and exercisable   26,531    212.33 
Unvested   26,935    38.46 

 

b)Fair Value of Options Issued During the Period

 

i)Weighted Average Fair Value at Grant Date of Options Granted:

 

The weighted average fair value at grant date of options granted during the three months ended September 30, 2022, was $6.00 per option (year ended June 30, 2022 - $21.04). Assumptions used for options granted during the three months ended September 30, 2022 included a weighted average risk-free interest rate of 3.59% (year ended June 30, 2022 – 1.17%), weighted average expected life of 3.3 years calculated using the Simplified Method for directors, officers and employees, weighted average volatility factor of 91.61% (year ended June 30, 2022 – 97.15%), weighted average dividend yield of 0% (year ended June 30, 2022 – 0%) and a 5% forfeiture rate (year ended June 30, 2022 – 5%).

 

ii)Expenses Arising from Share-based Payment Transactions:

 

Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2022, were $116,681 (2021 - $111,142). $65,072 was allocated to general and administrative expenses (2021 - $81,009) and the remaining $51,609 was allocated to research and development expenses (2021 - $30,133). Unrecognized compensation cost at September 30, 2022 related to unvested options was $154,239 which will be recognized over a weighted-average vesting period of 0.8 years.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations
3 Months Ended
Sep. 30, 2022
Leases [Abstract]  
LEASE OBLIGATIONS
10.LEASE OBLIGATIONS

 

The Company is committed to minimum lease payments as follows:

 

Maturity Analysis  September 30,
2022
 
   $ 
     
Less than one year   338,135 
One to five years   200,655 
More than five years   - 
Total undiscounted lease liabilities(1)   538,790 

 

(1)Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basic and Diluted Loss per Share
3 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
BASIC AND DILUTED LOSS PER SHARE
11.BASIC AND DILUTED LOSS PER SHARE

 

Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are anti-dilutive, they are excluded from the weighted average number of common shares in the table below.

 

   Three Months Ended 
   September 30, 
   2022   2021 
   $   $ 
         
Net loss for the period   (3,510,200)   (2,971,615)
Basic and diluted loss per share   (4.06)   (6.17)
Weighted average number of common shares - basic and diluted   865,619    481,902 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information
3 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION
12. SEGMENT INFORMATION

 

The following table presents information about the Company’s reportable segments for the three months ended September 30, 2022 and 2021:

 

    Three Months Ended September 30,  
    2022     2021  
    InMed     BayMedica     Total     InMed     BayMedica     Total  
    $     $     $     $     $     $  
                                     
Sales     -       320,788       320,788       -              -       -  
Operating expenses     2,268,831       1,562,157       3,830,988       2,971,615       -       2,971,615  
Net loss     (2,268,831 )     (1,241,369 )     (3,510,200 )     (2,971,615 )     -       (2,971,615 )
Unrestricted cash     9,227,828       122,599       9,350,427       15,343,905       -       15,343,905  
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Non-Cash Transactions
3 Months Ended
Sep. 30, 2022
Non Cash Transactions [Abstract]  
NON-CASH TRANSACTIONS
13.NON-CASH TRANSACTIONS

 

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. During the three months ended September 30, 2022, the following transactions were excluded from the statement of cash flows:

 

i)On September 13, 2022, the Company issued 44,931 preferred investment options to its placement agent. The fair value of these investment options was $451,897 and was included in share issuance costs related to the September 2022 private placement.

 

ii)As at September 30, 2022, the Company has unpaid financing costs of $106,185.

 

During the three months ended September 30, 2021, the following transactions were excluded from the statement of cash flows:

 

i)On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $739,920 and was included in share issuance costs related to the July 2021 private placement.

 

ii)As at September 30, 2021, the Company has unpaid financing costs of $179,118.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
3 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
14.COMMITMENTS AND CONTINGENCIES

 

Pursuant to the terms of agreements with various contract research organizations, as at September 30, 2022, the Company is committed for contract research services and materials at a cost of approximately $2,393,075. A total of $1,632,165 of these expenditures are expected to occur in the twelve months following September 30, 2022 and the balance of $760,910 in the following twelve month period.

 

Pursuant to the terms of agreements with various vendors, as at September 30, 2022, the Company is committed for contract materials and equipment at a cost of approximately $563,612, expected to occur in the twelve months following September 30, 2022.

 

Pursuant to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (“UBC”), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the agreement. To date, no payments have been required to be made.

 

Pursuant to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.

 

Pursuant to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable.

 

Short-term investments include guaranteed investment certificates with a face value of $42,125 (June 30, 2022 - $44,676) that are pledged as security for a corporate credit card.

 

The Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance limits the Company’s liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

 

Pursuant to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase 700 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.

 

The Company entered into a patent license agreement with a third party (the “Licensor”) in an agreement dated February 15, 2021. The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to 2022. As at September 30, 2022, the Company has paid $300,000 for the minimum payments under the agreement.

 

From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Risk Management
3 Months Ended
Sep. 30, 2022
Financial Risk Management [Abstract]  
FINANCIAL RISK MANAGEMENT
15.FINANCIAL RISK MANAGEMENT

 

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities.

 

The fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs.

 

a)Market Risk:

 

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk. The Company does not currently have significant commodity price risk or equity price risk.

 

Foreign Currency Risk:

 

Foreign currency risk is the risk that the future cash flows or fair value of the Company’s financial instruments that are denominated in a currency that is not the Company’s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates. Portions of the Company’s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.

 

Accordingly, the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.

 

As at September 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar denominated accounts payable and accrued liabilities of C$1,712,166 which is equivalent to US$1,249,196 at the September 30, 2022 exchange rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases of supplies and services from suppliers in Canada.

 

Each increase (decrease) of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain (loss), with a corresponding effect on cash flows, of $12,492 based on the September 30, 2022 net Canadian dollar assets (liabilities) position. During the three months ended September 30, 2022, the Company recorded foreign exchange loss of $94,392 (2021 – $83,800) related to Canadian dollars.

 

Interest Rate Risk:

 

Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at September 30, 2022, holdings of cash and cash equivalents of $8,061,484 (June 30, 2022 - $5,087,615) are subject to floating interest rates. The balance of the Company’s cash holdings of $1,288,943 (June 30, 2022 - $1,089,251) are non-interest bearing.

 

As at September 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $42,125 (June 30, 2022 - $44,676).

 

The Company’s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.

 

b)Credit Risk:

 

Credit risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents, short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.

 

The carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each reporting date.

 

c)Liquidity Risk:

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s policy is to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation. A key risk in managing liquidity is the degree of uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at September 30, 2022, the Company has cash and cash equivalents and short-term investments of $9,392,552 (June 30, 2022 - $6,221,670), current liabilities of $3,282,053 (June 30, 2022 - $3,181,316) and a working capital surplus of $8,260,856 (June 30, 2022 - $6,416,460).

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
3 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
16.RELATED PARTY TRANSACTIONS

 

On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP (“NRF”). During the three months ended September 30, 2022, NRF rendered legal services in the amount of $67,092 (2021 - $Nil) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were rendered by Ms. Grove directly.

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
3 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
17.SUBSEQUENT EVENTS

 

On October 13, 2022, in accordance with the BayMedica Agreement, $500,000 of escrow payments were made to BayMedica’s historical equity and convertible debt holders.

 

In October 2022, 341,226 of the September 2022 pre-funded warrants were exercised for a total of $34, resulting in the issuance of 341,226 common shares.

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounting Policies, by Policy (Policies)
3 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2022.

 

These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2022.

 

The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “$” and “US$” are to United States (“U.S.”) dollars and references to “C$” are to Canadian dollars.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.

 

COVID-19 Impacts

COVID-19 Impacts

 

The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.

 

Recent Accounting Pronouncements Not Yet Adopted

Recent Accounting Pronouncements Not Yet Adopted

 

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
3 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of inventories
   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Raw materials   292,577    292,577 
Work in process   1,210,261    1,724,851 
Finished goods   275,685    473,426 
Inventories   1,778,523    2,490,854 

 

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property, Equipment and Rou Assets, Net (Tables)
3 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
   September 30,
2022
   June 30,
2022
 
   $   $ 
           
Right-of-Use Assets (leases)   1,167,436    1,167,436 
Equipment   212,877    212,877 
Leasehold Improvements   40,409    40,409 
Property and equipment   1,420,722    1,420,722 
Less: accumulated depreciation and amortization   (618,353)   (516,470)
Property, equipment and ROU assets, net   802,369    904,252 

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Tables)
3 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Intellectual property   1,736,420    1,736,420 
Patents   1,191,000    1,191,000 
Intangible assets   2,927,420    2,927,420 
Less: accumulated depreciation   (859,498)   (818,505)
Intangible assets, net   2,067,922    2,108,915 

 

Schedule of amortization expense
   $ 
     
2023   155,778 
2024   155,778 
2025   155,778 
2026   155,778 
2027   155,778 
    778,890 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities (Tables)
3 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Schedule of accounts payable and accrued liabilities
   September 30,
2022
   June 30,
2022
 
   $   $ 
         
Trade payables   1,096,212    1,166,068 
Accrued research and development expenses   956,429    839,638 
Employee compensation, benefits and related accruals   249,593    139,120 
Accrued general and administrative expenses   59,956    270,439 
Accounts payable and accrued liabilities   2,362,190    2,415,265 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Tables)
3 Months Ended
Sep. 30, 2022
Share Capital And Reserves [Abstract]  
Schedule of Private Placement Offering
Transaction Description  Number   Issue Price   Total 
Shares Issued   90,000   $8.680   $781,200 
Pre-funded Warrants Issued   601,245   $8.6799    5,218,746 
Gross Proceeds            $5,999,946 
Allocated to Additional Paid-in Capital             (5,589,570)
             $410,376 
Share Issuance Costs            $(77,242)

 

Schedule of summary of changes in share purchase warrants
   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   244,767   $41.99         - 
Cancelled   (179,231)  $18.50    - 
Balance as at September 30, 2022   65,536   $106.23    - 

 

Schedule of changes in agents warrants
   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   12,109   $92.91         - 
Balance as at September 30, 2022   12,109   $92.91    - 

 

Schedule of changes in preferred investment options
   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   233,100   $18.50           - 
Granted   1,382,490   $8.44    - 
Cancelled   (233,100)  $18.50    - 
Balance as at September 30, 2022   1,382,490   $8.44    - 

 

Schedule of changes in agents' investment options
   Number   Weighted Average
Share Price
   Aggregate
Intrinsic Value
 
Balance as at June 30, 2022   15,152   $26.81           - 
Granted   44,931   $10.85    - 
Balance as at September 30, 2022   60,083   $14.88    - 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments (Tables)
3 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of options activity
   Number   Weighted Average
Exercise Price
$
 
Balance as at June 30, 2022   55,603    128.59 
Granted   560    9.75 
Expired/Forfeited   (2,697)   46.62 
Balance as at September 30, 2022   53,466    124.74 
           
September 30, 2022:          
Vested and exercisable   26,531    212.33 
Unvested   26,935    38.46 

 

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations (Tables)
3 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of minimum lease payments
Maturity Analysis  September 30,
2022
 
   $ 
     
Less than one year   338,135 
One to five years   200,655 
More than five years   - 
Total undiscounted lease liabilities(1)   538,790 

 

(1)Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basic and Diluted Loss per Share (Tables)
3 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of weighted average number of common shares
   Three Months Ended 
   September 30, 
   2022   2021 
   $   $ 
         
Net loss for the period   (3,510,200)   (2,971,615)
Basic and diluted loss per share   (4.06)   (6.17)
Weighted average number of common shares - basic and diluted   865,619    481,902 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
3 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of reportable segments
    Three Months Ended September 30,  
    2022     2021  
    InMed     BayMedica     Total     InMed     BayMedica     Total  
    $     $     $     $     $     $  
                                     
Sales     -       320,788       320,788       -              -       -  
Operating expenses     2,268,831       1,562,157       3,830,988       2,971,615       -       2,971,615  
Net loss     (2,268,831 )     (1,241,369 )     (3,510,200 )     (2,971,615 )     -       (2,971,615 )
Unrestricted cash     9,227,828       122,599       9,350,427       15,343,905       -       15,343,905  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Corporate Information and Continuing Operations (Details) - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Accounting Policies [Abstract]      
Net losses $ 3.5 $ 3.0  
Accumulated deficit 97.0   $ 93.5
Cash and cash equivalents $ 9.4    
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Customer Concentration (Details)
3 Months Ended
Sep. 30, 2022
Customer Concentration (Details) [Line Items]  
Net sales description The Company had three customers during the three months ended September 30, 2022, which individually generated 10% or more of the Company’s sales.
Customer One [Member] | Sales [Member]  
Customer Concentration (Details) [Line Items]  
Concentration percentage 78.00%
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Details) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Inventory Disclosure [Abstract]    
Inventory expensed to cost of goods sold $ 235,034
Write-down of inventories to net realizable value $ 576,772
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Details) - Schedule of inventories - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Schedule Of Inventories Abstract    
Raw materials $ 292,577 $ 292,577
Work in process 1,210,261 1,724,851
Finished goods 275,685 473,426
Inventories $ 1,778,523 $ 2,490,854
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property, Equipment and Rou Assets, Net (Details) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense on property, equipment and leasehold improvements $ 8,055 $ 4,217
Amortization expense related to the right-of-use assets $ 90,244 $ 21,343
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,420,722 $ 1,420,722
Less: accumulated depreciation and amortization (618,353) (516,470)
Property, equipment and ROU assets, net 802,369 904,252
Right-of-Use Assets (leases) [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,167,436 1,167,436
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 212,877 212,877
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 40,409 $ 40,409
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Details) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Intangible Assets (Details) [Line Items]    
Weighted average estimated remaining useful life 13 years  
Amortization expense on intangible assets (in Dollars) $ 40,993 $ 24,315
Term of amortization expense 5 years  
Intellectual property [Member]    
Intangible Assets (Details) [Line Items]    
Estimated useful life 18 years  
Patents [Member]    
Intangible Assets (Details) [Line Items]    
Estimated useful life 18 years  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Details) - Schedule of intangible assets - USD ($)
Sep. 30, 2022
Jun. 30, 2022
Schedule of Intangible Assets [Abstract]    
Intellectual property $ 1,736,420 $ 1,736,420
Patents 1,191,000 1,191,000
Intangible assets 2,927,420 2,927,420
Less: accumulated depreciation (859,498) (818,505)
Intangible assets, net $ 2,067,922 $ 2,108,915
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Details) - Schedule of amortization expense
Sep. 30, 2022
USD ($)
Schedule of Amortization Expense [Abstract]  
2023 $ 155,778
2024 155,778
2025 155,778
2026 155,778
2027 155,778
Total $ 778,890
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Schedule of Accounts Payable and Accrued Liabilities [Abstract]    
Trade payables $ 1,096,212 $ 1,166,068
Accrued research and development expenses 956,429 839,638
Employee compensation, benefits and related accruals 249,593 139,120
Accrued general and administrative expenses 59,956 270,439
Accounts payable and accrued liabilities $ 2,362,190 $ 2,415,265
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - USD ($)
3 Months Ended
Sep. 13, 2022
Sep. 13, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Capital and Reserves (Details) [Line Items]        
Common shares issued (in Shares)   90,000    
Pre-funded warrants   $ 601,245    
Gross proceeds from warrants   5,999,946    
Transaction costs allocated to common shares   77,242    
Transaction costs allocated to additional paid-in capital   $ 1,052,101    
Pre funded warrants outstanding (in Shares)     601,245  
Intrinsic value of warrants exercised      
IPO warrant issue (in Shares) 1,382,490      
Warrants exercise price (in Dollars per share) $ 8.44      
Warrants exercisable expire term 7 years      
Warrant [Member]        
Share Capital and Reserves (Details) [Line Items]        
Warrants exercise price (in Dollars per share) $ 10.85      
Warrants exercisable expire term 7 years      
Warrants issued (in Shares) 44,931      
Bay Medica Agreement [Member]        
Share Capital and Reserves (Details) [Line Items]        
Intrinsic value of warrants exercised      
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - Schedule of Private Placement Offering
3 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Total $ 410,376
Shares issued [Member]  
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Number of shares (in Shares) | shares 90,000
Issue Price (in Dollars per share) | $ / shares $ 8.68
Total $ 781,200
Pre-funded Warrants Issued [Member]  
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Number of shares (in Shares) | shares 601,245
Issue Price (in Dollars per share) | $ / shares $ 8.6799
Total $ 5,218,746
Gross Proceeds [Member]  
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Total 5,999,946
Allocated to Additional Paid-in Capital [Member]  
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Total (5,589,570)
Share Issuance Costs [Member]  
Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]  
Total $ (77,242)
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants
3 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants [Line Items]  
Number of Cancelled | shares (179,231)
Weighted Average Share Price, Cancelled | $ / shares $ 18.5
Aggregate Intrinsic Value, Cancelled | $
Share purchase warrants [Member]  
Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants [Line Items]  
Number of Beginning balance | shares 244,767
Weighted Average Share Price, Beginning balance | $ / shares $ 41.99
Aggregate Intrinsic Value, Beginning balance | $
Number of Ending balance | shares 65,536
Weighted Average Share Price, Ending balance | $ / shares $ 106.23
Aggregate Intrinsic Value, Ending balance | $
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - Schedule of changes in agents warrants - Agents Warrants [Member]
Sep. 30, 2022
USD ($)
$ / shares
shares
Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Line Items]  
Number of shares, Beginning balance | shares 12,109
Weighted Average Share Price, Beginning balance | $ / shares $ 92.91
Aggregate Intrinsic Value, Beginning balance | $
Number of shares, ending balance | shares 12,109
Weighted Average Share Price, ending balance | $ / shares $ 92.91
Aggregate Intrinsic Value, ending balance | $
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - Schedule of changes in preferred investment options - Preferred Investment Options [Member]
3 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share Capital and Reserves (Details) - Schedule of changes in preferred investment options [Line Items]  
Number of shares, Beginning balance | shares 233,100
Weighted Average Share Price, Beginning balance | $ / shares $ 18.5
Aggregate Intrinsic Value, Beginning balance | $
Number of shares, Granted | shares 1,382,490
Weighted Average Share Price, Granted | $ / shares $ 8.44
Aggregate Intrinsic Value, Granted | $
Number of shares, Cancelled | shares (233,100)
Weighted Average Share Price, Cancelled | $ / shares $ 18.5
Aggregate Intrinsic Value, Cancelled | $
Number of shares, ending balance | shares 1,382,490
Weighted Average Share Price, ending balance | $ / shares $ 8.44
Aggregate Intrinsic Value, ending balance | $
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share Capital and Reserves (Details) - Schedule of changes in agents' investment options - Agents’ Investment Options [Member]
3 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share Capital and Reserves (Details) - Schedule of changes in agents' investment options [Line Items]  
Number of shares, Beginning balance | shares 15,152
Weighted Average Share Price, Beginning balance | $ / shares $ 26.81
Aggregate Intrinsic Value, Beginning balance | $
Number of shares, Granted | shares 44,931
Weighted Average Share Price, Granted | $ / shares $ 10.85
Aggregate Intrinsic Value, Granted | $
Number of shares, ending balance | shares 60,083
Weighted Average Share Price, ending balance | $ / shares $ 14.88
Aggregate Intrinsic Value, ending balance | $
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 24, 2017
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Share-Based Payments (Details) [Line Items]        
Issued and outstanding, percentage 20.00% 20.00%    
Options shares (in Shares)   20,300   18,163
Weighted average fair value at grant date of options granted (in Dollars per share)   $ 6    
Weighted average fair value per share (in Dollars per share)       $ 21.04
Weighted average risk-free interest rate   3.59%   1.17%
Weighted average expected life   3 years 3 months 18 days    
Weighted average volatility rate   91.61%   97.15%
Weighted average dividend yield   0.00%   0.00%
Weighted average forfeiture rate   5.00%   5.00%
Share-based payment transactions (in Dollars)   $ 116,681 $ 111,142  
Unrecognized compensation cost (in Dollars)   $ 154,239    
Weighted-average vesting period   9 months 18 days    
General and Administrative Expenses [Member]        
Share-Based Payments (Details) [Line Items]        
Share-based payment transactions (in Dollars)   $ 65,072 81,009  
Research and Development Expenses [Member]        
Share-Based Payments (Details) [Line Items]        
Share-based payment transactions (in Dollars)   $ 51,609 $ 30,133  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments (Details) - Schedule of options activity
3 Months Ended
Sep. 30, 2022
$ / shares
shares
Schedule of Options Activity [Abstract]  
Number of Beginning balance 55,603
Weighted Average Exercise Price, Beginning balance (in Dollars per share) | $ / shares $ 128.59
Number of Granted 560
Weighted Average Exercise Price, Granted (in Dollars per share) | $ / shares $ 9.75
Number of Expired/Forfeited (2,697)
Weighted Average Exercise Price, Expired/Forfeited (in Dollars per share) | $ / shares $ 46.62
Number of Ending balance 53,466
Weighted Average Exercise Price, Ending balance 124.74
September 30, 2022:  
Number of Vested and exercisable 26,531
Weighted Average Exercise Price, Vested and exercisable (in Dollars per share) | $ / shares $ 212.33
Number of Unvested 26,935
Weighted Average Exercise Price, Unvested (in Dollars per share) | $ / shares $ 38.46
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations (Details) - USD ($)
1 Months Ended
Aug. 31, 2024
Apr. 30, 2024
Forecast [Member]    
Lease Obligations (Details) [Line Items]    
Variable operating costs $ 57,274 $ 92,964
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Lease Obligations (Details) - Schedule of minimum lease payments
Sep. 30, 2022
USD ($)
Schedule of Minimum Lease Payments [Abstract]  
Less than one year $ 338,135
One to five years 200,655
More than five years
Total undiscounted lease liabilities $ 538,790 [1]
[1] Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Schedule of Weighted Average Number of Common Shares [Abstract]    
Net loss for the period $ (3,510,200) $ (2,971,615)
Basic and diluted loss per share $ (4.06) $ (6.17)
Weighted average number of common shares - basic and diluted 865,619 481,902
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals) - $ / shares
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Schedule of Weighted Average Number of Common Shares [Abstract]    
Basic and diluted loss per share $ (4.06) $ (6.17)
Weighted average number of common shares - basic and diluted 865,619 481,902
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Details) - Schedule of reportable segments - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]    
Sales $ 320,788
Operating expenses 3,830,988 2,971,615
Net loss (3,510,200) (2,971,615)
Unrestricted cash 9,350,427 15,343,905
InMed [Member]    
Segment Reporting Information [Line Items]    
Sales
Operating expenses 2,268,831 2,971,615
Net loss (2,268,831) (2,971,615)
Unrestricted cash 9,227,828 15,343,905
BayMedica [Member]    
Segment Reporting Information [Line Items]    
Sales 320,788
Operating expenses 1,562,157
Net loss (1,241,369)
Unrestricted cash $ 122,599
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Non-Cash Transactions (Details) - USD ($)
Sep. 30, 2022
Sep. 13, 2022
Sep. 30, 2021
Jul. 02, 2021
Non Cash Transactions [Abstract]        
Preferred investment options issued (in Shares)   44,931    
Share issuance costs   $ 451,897   $ 739,920
Unpaid financing costs $ 106,185   $ 179,118  
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]      
Materials cost $ 2,393,075 $ 2,393,075  
Expenditure   1,632,165  
Balance of expenditure   760,910  
Materials and equipment at a cost 563,612    
Guaranteed investment face value $ 42,125 $ 42,125 $ 44,676
Warrants to purchase (in Shares) 700    
Common shares (in Shares) 700 700  
Accrued minimum payments $ 300,000 $ 300,000  
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Risk Management (Details)
3 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
CAD ($)
Jun. 30, 2022
USD ($)
Financial Risk Management (Details) [Line Items]        
Accounts payable and accrued liabilities $ 1,249,196   $ 1,712,166  
Cash and cash equivalents subject to floating interest rates 8,061,484     $ 5,087,615
Non-interest bearing 1,288,943     1,089,251
Guaranteed investment 42,125     44,676
Cash and cash equivalents and short-term investments 9,392,552     6,221,670
Current liabilities 3,282,053     3,181,316
Working capital surplus $ 8,260,856     $ 6,416,460
Canadian Dollar [Member]        
Financial Risk Management (Details) [Line Items]        
Increase decrease relation percentage 1.00%      
Effect on gain or loss $ 12,492      
Foreign exchange loss $ 94,392 $ 83,800    
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions (Details) - USD ($)
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Related Party Transactions [Abstract]    
Amount of legal services $ 67,092
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
1 Months Ended
Oct. 13, 2022
Oct. 31, 2022
Subsequent Events (Details) [Line Items]    
Pre-funded warrants   341,226
Exercised cost   $ 34
Issuance of common shares   341,226
BayMedica Agreement [Member]    
Subsequent Events (Details) [Line Items]    
Escrow payments $ 500,000  
XML 75 f10q0922_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-07-01 2022-09-30 0001728328 2022-11-14 0001728328 2022-09-30 0001728328 2022-06-30 0001728328 2021-07-01 2022-06-30 0001728328 2021-07-01 2021-09-30 0001728328 us-gaap:CommonStockMember 2021-06-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001728328 us-gaap:RetainedEarningsMember 2021-06-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001728328 2021-06-30 0001728328 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001728328 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001728328 us-gaap:CommonStockMember 2021-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001728328 us-gaap:RetainedEarningsMember 2021-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001728328 2021-09-30 0001728328 us-gaap:CommonStockMember 2022-06-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001728328 us-gaap:RetainedEarningsMember 2022-06-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001728328 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001728328 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001728328 us-gaap:CommonStockMember 2022-09-30 0001728328 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001728328 us-gaap:RetainedEarningsMember 2022-09-30 0001728328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001728328 inm:CustomerOneMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0001728328 inm:RightOfUseAssetMember 2022-09-30 0001728328 inm:RightOfUseAssetMember 2022-06-30 0001728328 us-gaap:EquipmentMember 2022-09-30 0001728328 us-gaap:EquipmentMember 2022-06-30 0001728328 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001728328 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001728328 us-gaap:IntellectualPropertyMember 2022-07-01 2022-09-30 0001728328 us-gaap:PatentsMember 2022-07-01 2022-09-30 0001728328 2021-09-01 2021-09-13 0001728328 inm:BayMedicaAgreementMember 2022-09-30 0001728328 2022-09-01 2022-09-13 0001728328 2022-09-13 0001728328 us-gaap:WarrantMember 2022-09-13 0001728328 us-gaap:WarrantMember 2022-09-01 2022-09-13 0001728328 inm:SharesIssuedMember 2022-07-01 2022-09-30 0001728328 inm:SharesIssuedMember 2022-09-30 0001728328 inm:PrivatePlacementPrefundedWarrantsMember 2022-07-01 2022-09-30 0001728328 inm:PrivatePlacementPrefundedWarrantsMember 2022-09-30 0001728328 inm:GrossProceedsMember 2022-07-01 2022-09-30 0001728328 inm:AllocatedToAdditionalPaidinCapitalMember 2022-07-01 2022-09-30 0001728328 inm:ShareIssuanceCostsMember 2022-07-01 2022-09-30 0001728328 inm:SharePurchaseWarrantsMember 2022-06-30 0001728328 inm:SharePurchaseWarrantsMember 2022-09-30 0001728328 inm:AgentsWarrantsMember 2022-06-30 0001728328 inm:AgentsWarrantsMember 2022-09-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-06-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-07-01 2022-09-30 0001728328 inm:PreferredInvestmentOptionsMember 2022-09-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-06-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-07-01 2022-09-30 0001728328 inm:AgentsInvestmentOptionsMember 2022-09-30 0001728328 2017-03-01 2017-03-24 0001728328 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001728328 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001728328 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001728328 srt:ScenarioForecastMember 2024-04-01 2024-04-30 0001728328 srt:ScenarioForecastMember 2024-08-01 2024-08-31 0001728328 inm:InMedMember 2022-07-01 2022-09-30 0001728328 inm:BayMedicaMember 2022-07-01 2022-09-30 0001728328 inm:InMedMember 2021-07-01 2021-09-30 0001728328 inm:BayMedicaMember 2021-07-01 2021-09-30 0001728328 inm:InMedMember 2022-09-30 0001728328 inm:BayMedicaMember 2022-09-30 0001728328 inm:InMedMember 2021-09-30 0001728328 inm:BayMedicaMember 2021-09-30 0001728328 2021-07-02 0001728328 2021-10-01 2022-09-30 0001728328 inm:CanadianDollarMember 2022-07-01 2022-09-30 0001728328 inm:CanadianDollarMember 2021-07-01 2021-09-30 0001728328 inm:BayMedicaAgreementMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-13 0001728328 us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001728328 us-gaap:SubsequentEventMember 2022-10-31 shares iso4217:USD iso4217:USD shares pure iso4217:CAD shares iso4217:CAD 10-Q true 2022-09-30 false 001-39685 INMED PHARMACEUTICALS INC. A1 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver B.C CA V6C 1B4 (604) 669-7207 Common Shares, no par value INM NASDAQ Yes Yes Non-accelerated Filer true true false false 936761 9350427 6176866 42125 44804 15169 88027 1778523 2490854 356665 797225 11542909 9597776 802369 904252 2067922 2108915 171130 176637 14584330 12787580 2362190 2415265 404163 404276 15700 500000 500000 3282053 3319541 294337 389498 3576390 3709039 908766 908766 650667 650667 72671392 70718461 35170766 31684098 -96962787 -93452587 128569 128569 11007940 9078541 14584330 12787580 320788 235034 576772 -491018 1378653 1491252 1560477 1372867 49048 28532 2988178 2892651 72587 5148 -96791 -84112 -3503400 -2971615 -6800 -3510200 -2971615 -4.06 -6.17 865619 481902 322028 60587417 21513051 -74852470 128569 7376567 35600 1459051 10540635 11999686 -247336 -1786831 -2034167 739920 739920 55453 1887592 -1887453 139 -2971615 -2971615 111142 111142 413081 63686724 29230464 -77824085 128569 15221672 650667 70718461 31684098 -93452587 128569 9078541 90000 410376 5589570 5999946 -77242 -1052101 -1129343 451897 451897 168099 1619797 -1619378 419 -3510200 -3510200 116680 116680 908766 72671392 35170766 -96962787 128569 11007940 -3510200 -2971615 49048 28532 116680 111142 99460 25906 -120 -23 -2796 -1262 576772 100903 17411 -135559 -440560 -634410 -5507 -6030 -72858 2923 -159260 -469227 15700 -2255543 -2653917 250000 -250000 6000365 11999825 571261 1115129 5429104 10884696 3173561 7980779 6176866 7363126 9350427 15343905 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs. The Company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s corporate office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through September 30, 2022, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of $3.5 million and $3.0 million for the three months ended September 30, 2022 and 2021, respectively. In addition, the Company had an accumulated deficit of $97.0 million as of September 30, 2022 (June 30, 2022 - $93.5 million). The Company expects to continue to generate operating losses for the foreseeable future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the issuance date of these condensed consolidated interim financial statements, the Company expects its cash and cash equivalents of $9.4 million as of September 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of fiscal 2023, and possibly into the first quarter of fiscal 2024 (being the third calendar quarter of 2023), depending on the level and timing of realizing revenues from the sale of BayMedica inventory as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. As a result of the recurring losses and requirement for cash in fiscal 2023 or the beginning of fiscal 2024, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to meet its commitments, realize its assets and discharge its liabilities in the normal course. These condensed consolidated interim financial statements do not reflect adjustments to the carrying values of assets and liabilities that would be necessary if the Company was unable to continue as a going concern and such adjustments could be material.</span></p> 3500000 3000000 97000000 93500000 9400000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “$” and “US$” are to United States (“U.S.”) dollars and references to “C$” are to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19 Impacts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States (“US GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for financial information. Accordingly, these financial statements do not include all the information and footnotes required for complete financial statements and should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated interim financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended September 30, 2022 and 2021 are not necessarily indicative of results that can be expected for a full year. These unaudited condensed consolidated interim financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of the Company and its subsidiaries is the U.S. Dollar. These condensed consolidated interim financial statements are presented in U.S. Dollars. References to “$” and “US$” are to United States (“U.S.”) dollars and references to “C$” are to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the estimate of useful life of intangible assets, the application of the going concern assumption, and determining the fair value of share-based payments and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19 Impacts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are evolving and highly uncertain, such as the duration and severity of outbreaks, including potential future waves or cycles, and the effectiveness of actions taken to contain and treat COVID-19. The Company considered the potential impact of COVID-19 when making certain estimates and judgments relating to the preparation of these consolidated financial statements. While there was no material impact to the Company’s condensed consolidated interim financial statements as of and for the three months ended September 30, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in a material impact to the Company’s consolidated financial statements in future reporting periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent Accounting Pronouncements Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the consolidated financial statements as a result of future adoption.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CUSTOMER CONCENTRATION</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had three customers during the three months ended September 30, 2022, which individually generated 10% or more of the Company’s sales. These customers accounted for 78% of the Company’s sales for the three months ended September 30, 2022. There were no outstanding amounts receivable from these customers as at September 30, 2022.</span></p> The Company had three customers during the three months ended September 30, 2022, which individually generated 10% or more of the Company’s sales. 0.78 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>292,577</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,577</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,210,261</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,724,851</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>275,685</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,426</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,778,523</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,490,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 30, 2022, inventory expensed to cost of goods sold was $235,034 (2021 - $<span style="-sec-ix-hidden: hidden-fact-47">Nil</span>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the three months ended September 30, 2022, the write-down of inventories to net realizable value was $576,772 (2021 - $<span style="-sec-ix-hidden: hidden-fact-48">Nil</span>). Contributing factors to the decrease in net realizable value included lower demand and downward pricing pressure.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>292,577</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,577</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,210,261</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,724,851</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>275,685</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">473,426</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,778,523</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,490,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 292577 292577 1210261 1724851 275685 473426 1778523 2490854 235034 576772 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY, EQUIPMENT AND ROU ASSETS, NET</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, equipment and ROU assets consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right-of-Use Assets (leases)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,167,436</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,167,436</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>212,877</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212,877</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>40,409</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,409</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,420,722</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,420,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(618,353</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(516,470</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Property, equipment and ROU assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>802,369</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">904,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense on property, equipment and leasehold improvements for the three months ended September 30, 2022, was $8,055 (2021 - $4,217). Amortization expense related to the right-of-use assets for the three months ended September 30, 2022, was $90,244 (2021 - $21,343) and was recorded in general and administrative expenses.</span></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right-of-Use Assets (leases)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,167,436</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,167,436</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>212,877</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212,877</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>40,409</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,409</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Property and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,420,722</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,420,722</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(618,353</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(516,470</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Property, equipment and ROU assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>802,369</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">904,252</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1167436 1167436 212877 212877 40409 40409 1420722 1420722 618353 516470 802369 904252 8055 4217 90244 21343 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSETS</b></span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intellectual property</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,736,420</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,191,000</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2,927,420</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(859,498</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(818,505</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2,067,922</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired intellectual property is recorded at cost and is amortized on a straight-line basis over 18 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired patents consist of patents related to the development of cannabinoid analogs. This intangible asset is being amortized over an estimated useful life of 18 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, the definite-lived intangible assets had a weighted average estimated remaining useful life of approximately 13 years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense on intangible assets for the three months ended September 30, 2022 was $40,993 (2021 - $24,315). The Company expects amortization expense to be incurred over the next five years as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">778,890</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>September 30,<br/> 2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intellectual property</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,736,420</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,736,420</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,191,000</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,191,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2,927,420</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927,420</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(859,498</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(818,505</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>2,067,922</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,108,915</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1736420 1736420 1191000 1191000 2927420 2927420 859498 818505 2067922 2108915 P18Y P18Y P13Y 40993 24315 P5Y <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,778</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">778,890</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 155778 155778 155778 155778 155778 778890 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities consist of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September 30, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,212</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,166,068</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued research and development expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">956,429</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">839,638</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee compensation, benefits and related accruals</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">249,593</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued general and administrative expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59,956</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">270,439</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued liabilities</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,362,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September 30, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">June 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade payables</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,096,212</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,166,068</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued research and development expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">956,429</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">839,638</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee compensation, benefits and related accruals</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">249,593</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued general and administrative expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59,956</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">270,439</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable and accrued liabilities</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,362,190</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,415,265</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1096212 1166068 956429 839638 249593 139120 59956 270439 2362190 2415265 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE CAPITAL AND RESERVES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, the Company’s authorized share structure consisted of: (i) an unlimited number of common shares without par value; and (ii) an unlimited number of preferred shares without par value. No preferred shares were issued and outstanding as at September 30, 2022 and June 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may issue preferred shares and may, at the time of issuance, determine the rights, preference and limitations pertaining to these shares. Holders of preferred shares may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding up of the Company before any payment is made to the holders of common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Shares</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 30, 2022, the Company completed the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 2022 Private Placement Offering:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Transaction Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issue Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif"><b>Shares Issued</b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>90,000</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.680</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>781,200</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Pre-funded Warrants Issued</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>601,245</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.6799</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,218,746</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Gross Proceeds</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,999,946</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Allocated to Additional Paid-in Capital</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(5,589,570</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>410,376</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"><b>Share Issuance Costs</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(77,242</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On September 13, 2022, the Company closed a private placement of its common shares and issued an aggregate of 90,000 common shares and 601,245 pre-funded warrants, for gross proceeds of $5,999,946. The pre-funded warrants were determined to be common stock equivalents. Each common share and each pre-funded warrant were sold in the offering with an investment option to purchase a common share. Transaction costs were allocated proportionally between common shares and investment options with $77,242 allocated to common shares and the balance of $1,052,101 allocated to additional paid-in capital and recorded as a component of shareholders’ equity in the consolidated balance sheet. As at September 30, 2022, there were 601,245 pre-funded warrants outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of changes in share purchase warrants from July 1, 2022 to September 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">244,767</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41.99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Cancelled</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(179,231</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18.50</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>65,536</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>106.23</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total intrinsic value of warrants exercised during the three months ended September 30, 2022 was $<span style="-sec-ix-hidden: hidden-fact-61">Nil</span> (2021 - $<span style="-sec-ix-hidden: hidden-fact-62">Nil</span>).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents’ Warrants</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of changes in agents’ warrants from July 1, 2022 to September 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.91</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>12,109</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>92.91</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Investment Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, 1,382,490 preferred investment options were issued with an exercise price of $8.44 per share, were immediately exercisable upon issuance, and expire 7 years following the date of issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">233,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">       -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Granted</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,382,490</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.44</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Cancelled</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(233,100</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18.50</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,382,490</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.44</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents’ Investment Options</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, 44,931 preferred investment options were issued for services with an exercise price of $10.85 per share, were immediately exercisable upon issuance, and expire approximately 7 years following the date of issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26.81</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">       -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,931</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.85</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at September 30, 2022</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,083</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.88</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Transaction Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issue Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif"><b>Shares Issued</b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>90,000</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.680</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>781,200</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Pre-funded Warrants Issued</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>601,245</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.6799</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,218,746</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Gross Proceeds</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>5,999,946</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Allocated to Additional Paid-in Capital</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(5,589,570</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>410,376</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"><b>Share Issuance Costs</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(77,242</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 90000 8.68 781200 601245 8.6799 5218746 5999946 -5589570 410376 -77242 90000 601245 5999946 77242 1052101 601245 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">244,767</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41.99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Cancelled</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(179,231</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18.50</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>65,536</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>106.23</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 244767 41.99 -179231 18.5 65536 106.23 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92.91</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">     -</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>12,109</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>92.91</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 12109 92.91 12109 92.91 1382490 8.44 P7Y <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">233,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">       -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Granted</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,382,490</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.44</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>Cancelled</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(233,100</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>18.50</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>1,382,490</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>8.44</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif"><b>-</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 233100 18.5 1382490 8.44 -233100 18.5 1382490 8.44 44931 10.85 P7Y <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/>Share Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26.81</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">       -</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,931</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.85</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as at September 30, 2022</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,083</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.88</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 15152 26.81 44931 10.85 60083 14.88 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHARE-BASED PAYMENTS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 18pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Plan Details</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 24, 2017, and as amended on November 20, 2020, the Company’s shareholders approved: (i) the adoption of a new stock option plan (the “Plan”) pursuant to which the Board of Directors may, from time to time, in its discretion and in accordance with regulatory requirements, grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed twenty percent (20%) of the issued and outstanding common shares at the date the options are granted (on a non-diluted and rolling basis); and (ii) the application of the new stock option plan to all outstanding stock options of the Company that were granted prior to March 24, 2017 under the terms of the Company’s previous stock option plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, there were 20,300 (June 30, 2022 – 18,163) options available for future allocation pursuant to SEC rules and 20% of the issued and outstanding shares according to the terms of the Plan. The option price under each option shall not be less than the closing price on the day prior to the date of grant. All options vest upon terms as set by the Board of Directors, either over time, up to 36 months, or upon the achievement of certain corporate milestones.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options granted prior to May 2021 were granted with Canadian dollar exercise prices (United States dollar amounts for weighted average exercise prices and aggregate intrinsic value are calculated using prevailing rates as at June 30, 2022). Commencing in May 2021, stock options are granted with United States dollar exercise prices.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of changes in outstanding options from July 1, 2022 to September 30, 2022:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/> Exercise Price<br/> $</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,603</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">128.59</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">560</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,697</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46.62</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>53,466</b></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>124.74</b></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>September 30, 2022:</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,531</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,935</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38.46</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value of Options Issued During the Period</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Fair Value at Grant Date of Options Granted:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average fair value at grant date of options granted during the three months ended September 30, 2022, was $6.00 per option (year ended June 30, 2022 - $21.04). Assumptions used for options granted during the three months ended September 30, 2022 included a weighted average risk-free interest rate of 3.59% (year ended June 30, 2022 – 1.17%), weighted average expected life of 3.3 years calculated using the Simplified Method for directors, officers and employees, weighted average volatility factor of 91.61% (year ended June 30, 2022 – 97.15%), weighted average dividend yield of 0% (year ended June 30, 2022 – 0%) and a 5% forfeiture rate (year ended June 30, 2022 – 5%).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses Arising from Share-based Payment Transactions:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total expenses arising from share-based payment transactions recognized during the three months ended September 30, 2022, were $116,681 (2021 - $111,142). $65,072 was allocated to general and administrative expenses (2021 - $81,009) and the remaining $51,609 was allocated to research and development expenses (2021 - $30,133). Unrecognized compensation cost at September 30, 2022 related to unvested options was $154,239 which will be recognized over a weighted-average vesting period of 0.8 years.</span></p> 0.20 20300 18163 0.20 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average <br/> Exercise Price<br/> $</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Balance as at June 30, 2022</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,603</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">128.59</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">560</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired/Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,697</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46.62</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>Balance as at September 30, 2022</b></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>53,466</b></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>124.74</b></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>September 30, 2022:</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,531</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,935</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38.46</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 55603 128.59 560 9.75 2697 46.62 53466 124.74 26531 212.33 26935 38.46 6 21.04 0.0359 0.0117 P3Y3M18D 0.9161 0.9715 0 0 0.05 0.05 116681 111142 65072 81009 51609 30133 154239 P0Y9M18D <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASE OBLIGATIONS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is committed to minimum lease payments as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Maturity Analysis</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,135</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">One to five years</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,655</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">More than five years</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total undiscounted lease liabilities<sup>(1)</sup></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,790</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup> </sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Maturity Analysis</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September 30,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less than one year</span></td><td style="width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,135</span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">One to five years</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,655</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">More than five years</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total undiscounted lease liabilities<sup>(1)</sup></span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">538,790</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup> </sup></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively.</span></td> </tr></table> 338135 200655 538790 92964 57274 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BASIC AND DILUTED LOSS PER SHARE</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share amounts are calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period. The pre-funded warrants were determined to be common stock equivalents and have been included in the weighted average number of shares outstanding for calculation of the basic earnings per share number. As the outstanding stock options and warrants are anti-dilutive, they are excluded from the weighted average number of common shares in the table below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(3,510,200</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,971,615</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-hidden: hidden-fact-65; -sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">Basic and diluted loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(4.06</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-hidden: hidden-fact-67; -sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">Weighted average number of common shares - basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>865,619</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">481,902</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>$</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(3,510,200</b></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,971,615</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-hidden: hidden-fact-65; -sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">Basic and diluted loss per share</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>(4.06</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>)</b></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-hidden: hidden-fact-67; -sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">Weighted average number of common shares - basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>865,619</b></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">481,902</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> -3510200 -2971615 -4.06 -6.17 865619 481902 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEGMENT INFORMATION</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following table presents information about the Company’s reportable segments for the three months ended September 30, 2022 and 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Months Ended September 30,</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InMed</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BayMedica</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InMed</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BayMedica</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>-</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>320,788</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>320,788</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 10pt">       -</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,268,831</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,562,157</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,830,988</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2,268,831</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1,241,369</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3,510,200</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrestricted cash</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9,227,828</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>122,599</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9,350,427</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,343,905</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,343,905</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="22" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Months Ended September 30,</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InMed</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BayMedica</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InMed</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BayMedica</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>-</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>320,788</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>320,788</b></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 10pt">       -</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2,268,831</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,562,157</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,830,988</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2,268,831</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1,241,369</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3,510,200</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,971,615</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrestricted cash</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9,227,828</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>122,599</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9,350,427</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,343,905</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,343,905</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 320788 320788 2268831 1562157 3830988 2971615 2971615 -2268831 -1241369 -3510200 -2971615 -2971615 9227828 122599 9350427 15343905 15343905 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NON-CASH TRANSACTIONS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing and financing activities that do not have a direct impact on cash flows are excluded from the statements of cash flows. During the three months ended September 30, 2022, the following transactions were excluded from the statement of cash flows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, the Company issued 44,931 preferred investment options to its placement agent. The fair value of these investment options was $451,897 and was included in share issuance costs related to the September 2022 private placement.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 20.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, the Company has unpaid financing costs of $106,185.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended September 30, 2021, the following transactions were excluded from the statement of cash flows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2021, the Company issued warrants to its placement agent. The fair value of these warrants was $739,920 and was included in share issuance costs related to the July 2021 private placement.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2021, the Company has unpaid financing costs of $179,118.</span></td></tr></table> 44931 451897 106185 739920 179118 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMITMENTS AND CONTINGENCIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of agreements with various contract research organizations, as at September 30, 2022, the Company is committed for contract research services and materials at a cost of approximately $2,393,075. A total of $1,632,165 of these expenditures are expected to occur in the twelve months following September 30, 2022 and the balance of $760,910 in the following twelve month period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of agreements with various vendors, as at September 30, 2022, the Company is committed for contract materials and equipment at a cost of approximately $563,612, expected to occur in the twelve months following September 30, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of a May 31, 2017 Technology Assignment Agreement between the Company and the University of British Columbia (“UBC”), the Company is committed to pay royalties to UBC on certain licensing and royalty revenues received by the Company for biosynthesis of certain drug products that are covered by the agreement. To date, no payments have been required to be made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of a December 13, 2018 Collaborative Research Agreement with UBC in which the Company owns all rights, title and interests in and to any intellectual property, in addition to funding research at UBC, the Company is committed to make a one-time payment upon filing of any PCT patent application arising from the research. To date, one such payment has been made to UBC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pursuant to the terms of a November 1, 2018 Contribution Agreement with National Research Council Canada, as represented by its Industrial Research Assistance Program (NRC-IRAP), under certain circumstances contributions received, including the disposition of the underlying intellectual property developed in part with NRC-IRAP contributions, may become repayable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Short-term investments include guaranteed investment certificates with a face value of $42,125 (June 30, 2022 - $44,676) that are pledged as security for a corporate credit card.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into certain agreements in the ordinary course of operations that may include indemnification provisions, which are common in such agreements. In some cases, the maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial general liability insurance. This insurance limits the Company’s liability and may enable the Company to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and it believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to a technology licensing agreement, the Company is committed to issue, subject to regulatory approval, up to 700 warrants to purchase 700 common shares upon the achievement of certain milestones. The exercise price of the warrants will be equal to the five-day VWAP of the common shares prior to each milestone achievement and the warrants will be exercisable for a period of three years for issuance date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a patent license agreement with a third party (the “Licensor”) in an agreement dated February 15, 2021. The Company is required to make future royalty payments to Licensor based on net sales of licensed products, with minimum payments required starting in 2021. In December 2021, the Company amended the License Agreement including the deferral of the 2021 minimum payments to 2022. As at September 30, 2022, the Company has paid $300,000 for the minimum payments under the agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</span></p> 2393075 1632165 760910 563612 42125 44676 700 700 300000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL RISK MANAGEMENT</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair values of short-term investments, accounts receivable, and accounts payable and accrued liabilities approximate their carrying values because of the short-term nature of these instruments. Cash and cash equivalents are measured at fair value using Level 1 inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices are comprised of four types of risk: foreign currency risk, interest rate risk, commodity price risk and equity price risk. The Company does not currently have significant commodity price risk or equity price risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign Currency Risk</i>:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency risk is the risk that the future cash flows or fair value of the Company’s financial instruments that are denominated in a currency that is not the Company’s functional currency (U.S. dollar) will fluctuate due to changes in foreign exchange rates. Portions of the Company’s cash and cash equivalents and accounts payable and accrued liabilities are denominated in Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, the Company is exposed to fluctuations in exchange rates, primarily against the Canadian dollar.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, the Company has a net excess of Canadian dollar denominated cash and cash equivalents in excess of Canadian dollar denominated accounts payable and accrued liabilities of C$1,712,166 which is equivalent to US$1,249,196 at the September 30, 2022 exchange rate. The Canadian dollar financial assets generally result from holding Canadian dollar cash to settle anticipated near-term accounts payable and accrued liabilities denominated in Canadian dollars. The Canadian dollar financial liabilities generally result from purchases of supplies and services from suppliers in Canada.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each increase (decrease) of 1% in the Canadian dollar in relation to the U.S. dollar results in a gain (loss), with a corresponding effect on cash flows, of $12,492 based on the September 30, 2022 net Canadian dollar assets (liabilities) position. During the three months ended September 30, 2022, the Company recorded foreign exchange loss of $94,392 (2021 – $83,800) related to Canadian dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest Rate Risk:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. As at September 30, 2022, holdings of cash and cash equivalents of $8,061,484 (June 30, 2022 - $5,087,615) are subject to floating interest rates. The balance of the Company’s cash holdings of $1,288,943 (June 30, 2022 - $1,089,251) are non-interest bearing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at September 30, 2022, the Company held variable rate guaranteed investment certificates, with one-year terms, of $42,125 (June 30, 2022 - $44,676).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s current policy is to invest excess cash in guaranteed investment certificates or interest-bearing accounts of major Canadian chartered banks or credit unions with comparable credit ratings. The Company regularly monitors compliance to its cash management policy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit risk is the risk of financial loss to the Company if a customer or a counter party to a financial instrument fails to meet its contractual obligations. Financial instruments which are potentially subject to credit risk for the Company consist primarily of cash and cash equivalents, short-term investments and loan receivable. Cash and cash equivalents and short-term investments are maintained with financial institutions of reputable credit and may be redeemed upon demand. In the normal course of business, the Company does not provide third party loans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of financial assets represents the maximum credit exposure. Credit risk exposure is limited through maintaining cash and cash equivalents and short-term investments with high-credit quality financial institutions and management considers this risk to be minimal for all cash and cash equivalents and short-term investments assets based on changes that are reasonably possible at each reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity Risk:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company’s policy is to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation. A key risk in managing liquidity is the degree of uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases. As at September 30, 2022, the Company has cash and cash equivalents and short-term investments of $9,392,552 (June 30, 2022 - $6,221,670), current liabilities of $3,282,053 (June 30, 2022 - $3,181,316) and a working capital surplus of $8,260,856 (June 30, 2022 - $6,416,460).</span></p> 1712166 1249196 0.01 12492 94392 83800 8061484 5087615 1288943 1089251 42125 44676 9392552 6221670 3282053 3181316 8260856 6416460 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED PARTY TRANSACTIONS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2022, the Board of Directors appointed Janet Grove as a director of the Company. Ms. Grove is a Partner of Norton Rose Fulbright Canada LLP (“NRF”). During the three months ended September 30, 2022, NRF rendered legal services in the amount of $67,092 (2021 - $<span style="-sec-ix-hidden: hidden-fact-75">Nil</span>) to the Company. These transactions were in the normal course of operations and were measured at the exchange amount which represented the amount of consideration established and agreed to by NRF. No legal services rendered by NRF were rendered by Ms. Grove directly.</span></p> 67092 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBSEQUENT EVENTS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2022, in accordance with the BayMedica Agreement, $500,000 of escrow payments were made to BayMedica’s historical equity and convertible debt holders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -1.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, 341,226 of the September 2022 pre-funded warrants were exercised for a total of $34, resulting in the issuance of 341,226 common shares.</span></p> 500000 341226 34 341226 Unlimited Unlimited -4.06 -6.17 481902 865619 -4.06 -6.17 481902 865619 false --06-30 Q1 2023 0001728328 Excludes estimated variable operating costs of $92,964 and $57,274 on an annual basis through to April 30, 2024 and August 31, 2024, respectively. EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 86 264 1 true 29 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet Condensed Consolidated Interim Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Interim Statements of Shareholders??? Equity (Unaudited) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3 Condensed Consolidated Interim Statements of Shareholders??? Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Corporate Information and Continuing Operations Sheet http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations Corporate Information and Continuing Operations Notes 8 false false R9.htm 008 - Disclosure - Significant Accounting Policies Sheet http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Customer Concentration Sheet http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration Customer Concentration Notes 10 false false R11.htm 010 - Disclosure - Inventories Sheet http://www.Inmedpharmaceuticalsinc.com/role/Inventories Inventories Notes 11 false false R12.htm 011 - Disclosure - Property, Equipment and Rou Assets, Net Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet Property, Equipment and Rou Assets, Net Notes 12 false false R13.htm 012 - Disclosure - Intangible Assets Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 013 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 14 false false R15.htm 014 - Disclosure - Share Capital and Reserves Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves Share Capital and Reserves Notes 15 false false R16.htm 015 - Disclosure - Share-Based Payments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments Share-Based Payments Notes 16 false false R17.htm 016 - Disclosure - Lease Obligations Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations Lease Obligations Notes 17 false false R18.htm 017 - Disclosure - Basic and Diluted Loss per Share Sheet http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShare Basic and Diluted Loss per Share Notes 18 false false R19.htm 018 - Disclosure - Segment Information Sheet http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation Segment Information Notes 19 false false R20.htm 019 - Disclosure - Non-Cash Transactions Sheet http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions Non-Cash Transactions Notes 20 false false R21.htm 020 - Disclosure - Commitments and Contingencies Sheet http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 021 - Disclosure - Financial Risk Management Sheet http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement Financial Risk Management Notes 22 false false R23.htm 022 - Disclosure - Related Party Transactions Sheet http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 023 - Disclosure - Subsequent Events Sheet http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 024 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies 25 false false R26.htm 025 - Disclosure - Inventories (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables Inventories (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/Inventories 26 false false R27.htm 026 - Disclosure - Property, Equipment and Rou Assets, Net (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables Property, Equipment and Rou Assets, Net (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet 27 false false R28.htm 027 - Disclosure - Intangible Assets (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets 28 false false R29.htm 028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities 29 false false R30.htm 029 - Disclosure - Share Capital and Reserves (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables Share Capital and Reserves (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves 30 false false R31.htm 030 - Disclosure - Share-Based Payments (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments 31 false false R32.htm 031 - Disclosure - Lease Obligations (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations 32 false false R33.htm 032 - Disclosure - Basic and Diluted Loss per Share (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShareTables Basic and Diluted Loss per Share (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShare 33 false false R34.htm 033 - Disclosure - Segment Information (Tables) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation 34 false false R35.htm 034 - Disclosure - Corporate Information and Continuing Operations (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails Corporate Information and Continuing Operations (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations 35 false false R36.htm 035 - Disclosure - Customer Concentration (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails Customer Concentration (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration 36 false false R37.htm 036 - Disclosure - Inventories (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails Inventories (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables 37 false false R38.htm 037 - Disclosure - Inventories (Details) - Schedule of inventories Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable Inventories (Details) - Schedule of inventories Details http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables 38 false false R39.htm 038 - Disclosure - Property, Equipment and Rou Assets, Net (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails Property, Equipment and Rou Assets, Net (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables 39 false false R40.htm 039 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment Details http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables 40 false false R41.htm 040 - Disclosure - Intangible Assets (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 41 false false R42.htm 041 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable Intangible Assets (Details) - Schedule of intangible assets Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 42 false false R43.htm 042 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable Intangible Assets (Details) - Schedule of amortization expense Details http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables 43 false false R44.htm 043 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities Details http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables 44 false false R45.htm 044 - Disclosure - Share Capital and Reserves (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails Share Capital and Reserves (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 45 false false R46.htm 045 - Disclosure - Share Capital and Reserves (Details) - Schedule of Private Placement Offering Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable Share Capital and Reserves (Details) - Schedule of Private Placement Offering Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 46 false false R47.htm 046 - Disclosure - Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 47 false false R48.htm 047 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable Share Capital and Reserves (Details) - Schedule of changes in agents warrants Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 48 false false R49.htm 048 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in preferred investment options Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable Share Capital and Reserves (Details) - Schedule of changes in preferred investment options Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 49 false false R50.htm 049 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents' investment options Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable Share Capital and Reserves (Details) - Schedule of changes in agents' investment options Details http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables 50 false false R51.htm 050 - Disclosure - Share-Based Payments (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails Share-Based Payments (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables 51 false false R52.htm 051 - Disclosure - Share-Based Payments (Details) - Schedule of options activity Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable Share-Based Payments (Details) - Schedule of options activity Details http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables 52 false false R53.htm 052 - Disclosure - Lease Obligations (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails Lease Obligations (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables 53 false false R54.htm 053 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable Lease Obligations (Details) - Schedule of minimum lease payments Details http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables 54 false false R55.htm 054 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares Details http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShareTables 55 false false R56.htm 055 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals) Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals) Details http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShareTables 56 false false R57.htm 056 - Disclosure - Segment Information (Details) - Schedule of reportable segments Sheet http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable Segment Information (Details) - Schedule of reportable segments Details http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables 57 false false R58.htm 057 - Disclosure - Non-Cash Transactions (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails Non-Cash Transactions (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions 58 false false R59.htm 058 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies 59 false false R60.htm 059 - Disclosure - Financial Risk Management (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails Financial Risk Management (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement 60 false false R61.htm 060 - Disclosure - Related Party Transactions (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions 61 false false R62.htm 061 - Disclosure - Subsequent Events (Details) Sheet http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents 62 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10q0922_inmedpharma.htm 5604, 5605, 5606, 5607, 5659, 5660, 5661, 5662 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommonStockNoParValue, us-gaap:CommonStockSharesAuthorizedUnlimited - f10q0922_inmedpharma.htm 5597, 5598, 5599 f10q0922_inmedpharma.htm f10q0922ex31-1_inmedpharma.htm f10q0922ex31-2_inmedpharma.htm f10q0922ex32-1_inmedpharma.htm f10q0922ex32-2_inmedpharma.htm inm-20220930.xsd inm-20220930_cal.xml inm-20220930_def.xml inm-20220930_lab.xml inm-20220930_pre.xml fin_001.jpg image_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0922_inmedpharma.htm": { "axisCustom": 1, "axisStandard": 11, "contextCount": 86, "dts": { "calculationLink": { "local": [ "inm-20220930_cal.xml" ] }, "definitionLink": { "local": [ "inm-20220930_def.xml" ] }, "inline": { "local": [ "f10q0922_inmedpharma.htm" ] }, "labelLink": { "local": [ "inm-20220930_lab.xml" ] }, "presentationLink": { "local": [ "inm-20220930_pre.xml" ] }, "schema": { "local": [ "inm-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 413, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 46, "http://www.Inmedpharmaceuticalsinc.com/20220930": 30, "http://xbrl.sec.gov/dei/2022": 5, "total": 81 }, "keyCustom": 68, "keyStandard": 196, "memberCustom": 15, "memberStandard": 14, "nsprefix": "inm", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Customer Concentration", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration", "shortName": "Customer Concentration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Inventories", "role": "http://www.Inmedpharmaceuticalsinc.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Property, Equipment and Rou Assets, Net", "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet", "shortName": "Property, Equipment and Rou Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Intangible Assets", "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ShareCapitalAndReservesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Share Capital and Reserves", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves", "shortName": "Share Capital and Reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ShareCapitalAndReservesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Share-Based Payments", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments", "shortName": "Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Lease Obligations", "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Basic and Diluted Loss per Share", "role": "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShare", "shortName": "Basic and Diluted Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Segment Information", "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Interim Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:NonCashTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Non-Cash Transactions", "role": "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions", "shortName": "Non-Cash Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:NonCashTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Commitments and Contingencies", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:FinancialRiskManagementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Financial Risk Management", "role": "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement", "shortName": "Financial Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:FinancialRiskManagementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Related Party Transactions", "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Subsequent Events", "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Inventories (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Property, Equipment and Rou Assets, Net (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables", "shortName": "Property, Equipment and Rou Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Intangible Assets (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ScheduleOfCommonSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Share Capital and Reserves (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables", "shortName": "Share Capital and Reserves (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ScheduleOfCommonSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Share-Based Payments (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables", "shortName": "Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Lease Obligations (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Basic and Diluted Loss per Share (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShareTables", "shortName": "Basic and Diluted Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "inm:ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Segment Information (Tables)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Corporate Information and Continuing Operations (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails", "shortName": "Corporate Information and Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCustomer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Customer Concentration (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails", "shortName": "Customer Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCustomer", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "inm:InventoryExpensed", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Inventories (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "inm:InventoryExpensed", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Inventories (Details) - Schedule of inventories", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable", "shortName": "Inventories (Details) - Schedule of inventories", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Property, Equipment and Rou Assets, Net (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails", "shortName": "Property, Equipment and Rou Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable", "shortName": "Property, Equipment and Rou Assets, Net (Details) - Schedule of property and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Intangible Assets (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Intangible Assets (Details) - Schedule of amortization expense", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable", "shortName": "Intangible Assets (Details) - Schedule of amortization expense", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable", "shortName": "Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c41", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Share Capital and Reserves (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "shortName": "Share Capital and Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c41", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesOther", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "inm:ScheduleOfCommonSharesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "inm:TotalCommonShareValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Share Capital and Reserves (Details) - Schedule of Private Placement Offering", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable", "shortName": "Share Capital and Reserves (Details) - Schedule of Private Placement Offering", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "inm:ScheduleOfCommonSharesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "inm:TotalCommonShareValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareOfNumberOfCancelled", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable", "shortName": "Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "inm:ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareOfNumberOfCancelled", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c56", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents warrants", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "shortName": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "inm:ScheduleOfChangesInAgentsWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c56", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c58", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in preferred investment options", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable", "shortName": "Share Capital and Reserves (Details) - Schedule of changes in preferred investment options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c58", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "inm:ScheduleOfChangesInAgentsInvestmentOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c61", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Share Capital and Reserves (Details) - Schedule of changes in agents' investment options", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "shortName": "Share Capital and Reserves (Details) - Schedule of changes in agents' investment options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "inm:ScheduleOfChangesInAgentsInvestmentOptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c61", "decimals": "INF", "first": true, "lang": null, "name": "inm:ShareBasedPaymentNumberOfBalanceAtBeginning", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c64", "decimals": "2", "first": true, "lang": null, "name": "inm:IssuedAndOutstandingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Share-Based Payments (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails", "shortName": "Share-Based Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c64", "decimals": "2", "first": true, "lang": null, "name": "inm:IssuedAndOutstandingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Share-Based Payments (Details) - Schedule of options activity", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable", "shortName": "Share-Based Payments (Details) - Schedule of options activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "inm:SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c70", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Lease Obligations (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails", "shortName": "Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c70", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Lease Obligations (Details) - Schedule of minimum lease payments", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable", "shortName": "Lease Obligations (Details) - Schedule of minimum lease payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable", "shortName": "Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals", "shortName": "Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Segment Information (Details) - Schedule of reportable segments", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable", "shortName": "Segment Information (Details) - Schedule of reportable segments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c44", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Non-Cash Transactions (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails", "shortName": "Non-Cash Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c44", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "inm:CostOfServicesDirectsMaterials", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c80", "decimals": "0", "lang": null, "name": "us-gaap:CapitalExpenditureDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Interim Statements of Shareholders\u2019 Equity (Unaudited)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Interim Statements of Shareholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Financial Risk Management (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails", "shortName": "Financial Risk Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Related Party Transactions (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Subsequent Events (Details)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "b", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "role": "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Corporate Information and Continuing Operations", "role": "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations", "shortName": "Corporate Information and Continuing Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Significant Accounting Policies", "role": "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0922_inmedpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 29, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "inm_AccountsPayableandAccruedLiabilitiesDetailsScheduleofaccountspayableandaccruedliabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Abstract]" } } }, "localname": "AccountsPayableandAccruedLiabilitiesDetailsScheduleofaccountspayableandaccruedliabilitiesLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "stringItemType" }, "inm_AccountsPayableandAccruedLiabilitiesDetailsScheduleofaccountspayableandaccruedliabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities [Table]" } } }, "localname": "AccountsPayableandAccruedLiabilitiesDetailsScheduleofaccountspayableandaccruedliabilitiesTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "stringItemType" }, "inm_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "inm_AcquisitionConsiderationPayable": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition consideration payable.", "label": "Acquisition Consideration Payable", "terseLabel": "Acquisition consideration payable" } } }, "localname": "AcquisitionConsiderationPayable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "inm_AgentsInvestmentOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of agents' investment options.", "label": "Agents Investment Options", "terseLabel": "Agents\u2019 investment options" } } }, "localname": "AgentsInvestmentOptions", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "inm_AgentsInvestmentOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agents Investment Options Member", "terseLabel": "Agents\u2019 Investment Options [Member]" } } }, "localname": "AgentsInvestmentOptionsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable" ], "xbrltype": "domainItemType" }, "inm_AgentsWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of agents\u2019 warrants.\r \n.", "label": "Agents Warrants", "terseLabel": "Agents\u2019 warrants" } } }, "localname": "AgentsWarrants", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "inm_AgentsWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agents Warrants Member", "terseLabel": "Agents Warrants [Member]" } } }, "localname": "AgentsWarrantsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable" ], "xbrltype": "domainItemType" }, "inm_AggregateIntrinsicValueAtBeginning": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value At Beginning", "periodEndLabel": "Aggregate Intrinsic Value, Ending balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance" } } }, "localname": "AggregateIntrinsicValueAtBeginning", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "monetaryItemType" }, "inm_AggregateIntrinsicValueCancelled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate intrinsic value cancelled.", "label": "Aggregate Intrinsic Value Cancelled", "terseLabel": "Aggregate Intrinsic Value, Cancelled" } } }, "localname": "AggregateIntrinsicValueCancelled", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "monetaryItemType" }, "inm_AllocatedToAdditionalPaidinCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Allocated To Additional Paidin Capital Member", "terseLabel": "Allocated to Additional Paid-in Capital [Member]" } } }, "localname": "AllocatedToAdditionalPaidinCapitalMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "inm_BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Number of Common Shares [Abstract]" } } }, "localname": "BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable" ], "xbrltype": "stringItemType" }, "inm_BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesParentheticalsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basicand Diluted Lossper Share Details Scheduleofweightedaveragenumberofcommonshares Parentheticals Line Items", "terseLabel": "Schedule of Weighted Average Number of Common Shares [Abstract]" } } }, "localname": "BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesParentheticalsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "stringItemType" }, "inm_BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesParentheticalsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares (Parentheticals) [Table]" } } }, "localname": "BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesParentheticalsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "stringItemType" }, "inm_BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss per Share (Details) - Schedule of weighted average number of common shares [Table]" } } }, "localname": "BasicandDilutedLossperShareDetailsScheduleofweightedaveragenumberofcommonsharesTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable" ], "xbrltype": "stringItemType" }, "inm_BayMedicaAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bay Medica Agreement Member", "terseLabel": "Bay Medica Agreement [Member]", "verboseLabel": "BayMedica Agreement [Member]" } } }, "localname": "BayMedicaAgreementMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "inm_BayMedicaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bay Medica Member", "terseLabel": "BayMedica [Member]" } } }, "localname": "BayMedicaMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "domainItemType" }, "inm_COVID19ImpactsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID19 Impacts Policy Text Block", "terseLabel": "COVID-19 Impacts" } } }, "localname": "COVID19ImpactsPolicyTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "inm_CanadianDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canadian Dollar Member", "terseLabel": "Canadian Dollar [Member]", "verboseLabel": "U.S. Dollar [Member]" } } }, "localname": "CanadianDollarMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "domainItemType" }, "inm_CashAndCashEquivalent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash And Cash Equivalent", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalent", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "inm_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "percentItemType" }, "inm_CorporateInformationandContinuingOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Corporate Information and Continuing Operations [Abstract]" } } }, "localname": "CorporateInformationandContinuingOperationsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations" ], "xbrltype": "stringItemType" }, "inm_CorporateInformationandContinuingOperationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Corporate Information and Continuing Operations [Table]" } } }, "localname": "CorporateInformationandContinuingOperationsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations" ], "xbrltype": "stringItemType" }, "inm_CostOfServicesDirectsMaterials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of materials used in services rendered by an entity during the reporting period.", "label": "Cost Of Services Directs Materials", "terseLabel": "Materials cost" } } }, "localname": "CostOfServicesDirectsMaterials", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "inm_CustomerConcentrationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Line Items]" } } }, "localname": "CustomerConcentrationDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "inm_CustomerConcentrationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Table]" } } }, "localname": "CustomerConcentrationDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "inm_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer One Member", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "inm_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_EscrowPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An escrow account is a third party account where funds are kept before they are transferred to the ultimate party.", "label": "Escrow Payments", "terseLabel": "Escrow payments" } } }, "localname": "EscrowPayments", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "inm_EstimatedFairValueCommonShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated fair value common shares.", "label": "Estimated Fair Value Common Shares", "terseLabel": "Share issuance costs" } } }, "localname": "EstimatedFairValueCommonShares", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "inm_ExerciseOfPrefundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of pre-funded warrants.", "label": "Exercise Of Prefunded Warrants", "terseLabel": "Exercise of pre-funded warrants" } } }, "localname": "ExerciseOfPrefundedWarrants", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "inm_ExerciseOfPrefundedWarrantsinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares exercise of pre-funded warrants.", "label": "Exercise Of Prefunded Warrantsin Shares", "terseLabel": "Exercise of pre-funded warrants (in Shares)" } } }, "localname": "ExerciseOfPrefundedWarrantsinShares", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "inm_ExpenditureBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The balance of expenditure is the balance of spending against the amount of available funds. While this may seem to be a relatively simple process, balancing expenditures can be complex when credit accounts, payables and receivables become involved.", "label": "Expenditure Balance", "terseLabel": "Balance of expenditure" } } }, "localname": "ExpenditureBalance", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "inm_FinancialRiskManagementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Risk Management [Abstract]" } } }, "localname": "FinancialRiskManagementAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_FinancialRiskManagementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Risk Management (Details) [Line Items]" } } }, "localname": "FinancialRiskManagementDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "stringItemType" }, "inm_FinancialRiskManagementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Risk Management (Details) [Table]" } } }, "localname": "FinancialRiskManagementDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "stringItemType" }, "inm_FinancialRiskManagementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Risk Management Text Block", "terseLabel": "FINANCIAL RISK MANAGEMENT" } } }, "localname": "FinancialRiskManagementTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagement" ], "xbrltype": "textBlockItemType" }, "inm_FiniteLivedIntangibleAssetNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Asset Net", "terseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetNet", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "inm_ForeignCurrencyRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign currency risk, percentage.", "label": "Foreign Currency Risk Percentage", "terseLabel": "Increase decrease relation percentage" } } }, "localname": "ForeignCurrencyRiskPercentage", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "percentItemType" }, "inm_GrossProceedsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Proceeds Member", "terseLabel": "Gross Proceeds [Member]" } } }, "localname": "GrossProceedsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "inm_GuaranteedInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Guaranteed investment.", "label": "Guaranteed Investment", "terseLabel": "Guaranteed investment face value" } } }, "localname": "GuaranteedInvestment", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "inm_IPOWarrantIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IPOWarrant Issue", "terseLabel": "IPO warrant issue (in Shares)" } } }, "localname": "IPOWarrantIssue", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "sharesItemType" }, "inm_InMedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In Med Member", "terseLabel": "InMed [Member]" } } }, "localname": "InMedMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "domainItemType" }, "inm_IntangibleAssetsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Line Items]" } } }, "localname": "IntangibleAssetsDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "inm_IntangibleAssetsDetailsScheduleofamortizationexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Amortization Expense [Abstract]" } } }, "localname": "IntangibleAssetsDetailsScheduleofamortizationexpenseLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "stringItemType" }, "inm_IntangibleAssetsDetailsScheduleofamortizationexpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of amortization expense [Table]" } } }, "localname": "IntangibleAssetsDetailsScheduleofamortizationexpenseTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "stringItemType" }, "inm_IntangibleAssetsDetailsScheduleofintangibleassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets [Abstract]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "inm_IntangibleAssetsDetailsScheduleofintangibleassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Table]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "inm_IntangibleAssetsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "localname": "IntangibleAssetsDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "inm_InterestIncomeaccruedReceivedOnShorttermInvestments": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest income (accrued) received on short-term investments.", "label": "Interest Incomeaccrued Received On Shortterm Investments", "terseLabel": "Interest income received on short-term investments" } } }, "localname": "InterestIncomeaccruedReceivedOnShorttermInvestments", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "inm_InventoryExpensed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Inventory Expensed", "terseLabel": "Inventory expensed to cost of goods sold" } } }, "localname": "InventoryExpensed", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "inm_InventoryWritedowninDollarsPerShare": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory write down in dollars per share.", "label": "Inventory Writedownin Dollars Per Share", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWritedowninDollarsPerShare", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "inm_IssuedAndOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and outstanding, percentage", "label": "Issued And Outstanding Percentage", "terseLabel": "Issued and outstanding, percentage" } } }, "localname": "IssuedAndOutstandingPercentage", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "inm_LeaseObligationsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Obligations (Details) [Line Items]" } } }, "localname": "LeaseObligationsDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "xbrltype": "stringItemType" }, "inm_LeaseObligationsDetailsScheduleofminimumleasepaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Minimum Lease Payments [Abstract]" } } }, "localname": "LeaseObligationsDetailsScheduleofminimumleasepaymentsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "stringItemType" }, "inm_LeaseObligationsDetailsScheduleofminimumleasepaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Obligations (Details) - Schedule of minimum lease payments [Table]" } } }, "localname": "LeaseObligationsDetailsScheduleofminimumleasepaymentsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "stringItemType" }, "inm_LeaseObligationsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Obligations (Details) [Table]" } } }, "localname": "LeaseObligationsDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "xbrltype": "stringItemType" }, "inm_NetProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds.", "label": "Net Proceeds", "terseLabel": "Exercised cost" } } }, "localname": "NetProceeds", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "inm_NonCashTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Cash Transactions [Abstract]" } } }, "localname": "NonCashTransactionsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_NonCashTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Cash Transactions Text Block", "terseLabel": "NON-CASH TRANSACTIONS" } } }, "localname": "NonCashTransactionsTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactions" ], "xbrltype": "textBlockItemType" }, "inm_NumberOfEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares.", "label": "Number Of Ending Balance", "periodEndLabel": "Number of shares, ending balance" } } }, "localname": "NumberOfEndingBalance", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "sharesItemType" }, "inm_NumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares.", "label": "Number Of Shares", "terseLabel": "Number of shares (in Shares)" } } }, "localname": "NumberOfShares", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "sharesItemType" }, "inm_NumberOfUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of unvested.", "label": "Number Of Unvested", "terseLabel": "Number of Unvested" } } }, "localname": "NumberOfUnvested", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "inm_NumberOfVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Vested and exercisable.", "label": "Number Of Vested And Exercisable", "terseLabel": "Number of Vested and exercisable" } } }, "localname": "NumberOfVestedAndExercisable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "inm_PreFundedWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre funded warrants outstanding.", "label": "Pre Funded Warrants Outstanding", "terseLabel": "Pre funded warrants outstanding (in Shares)" } } }, "localname": "PreFundedWarrantsOutstanding", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "sharesItemType" }, "inm_PreferredInvestmentOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Investment Options Member", "terseLabel": "Preferred Investment Options [Member]" } } }, "localname": "PreferredInvestmentOptionsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "domainItemType" }, "inm_PrefundedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prefunded Warrants", "terseLabel": "Pre-funded warrants" } } }, "localname": "PrefundedWarrants", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "monetaryItemType" }, "inm_PrivatePlacementPrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Prefunded Warrants Member", "terseLabel": "Pre-funded Warrants Issued [Member]" } } }, "localname": "PrivatePlacementPrefundedWarrantsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "inm_RightOfUseAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Right Of Use Asset Member", "terseLabel": "Right-of-Use Assets (leases) [Member]" } } }, "localname": "RightOfUseAssetMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "inm_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Accounts Payable And Accrued Liabilities Abstract" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Amortization Expense Abstract" } } }, "localname": "ScheduleOfAmortizationExpenseAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfChangesInAgentsInvestmentOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Agents Investment Options Abstract" } } }, "localname": "ScheduleOfChangesInAgentsInvestmentOptionsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfChangesInAgentsInvestmentOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Agents Investment Options Table Text Block", "terseLabel": "Schedule of changes in agents' investment options" } } }, "localname": "ScheduleOfChangesInAgentsInvestmentOptionsTableTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "xbrltype": "textBlockItemType" }, "inm_ScheduleOfChangesInAgentsWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Agents Warrants Abstract" } } }, "localname": "ScheduleOfChangesInAgentsWarrantsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfChangesInAgentsWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of changes in agents warrants.", "label": "Schedule Of Changes In Agents Warrants Table Text Block", "terseLabel": "Schedule of changes in agents warrants" } } }, "localname": "ScheduleOfChangesInAgentsWarrantsTableTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "xbrltype": "textBlockItemType" }, "inm_ScheduleOfChangesInPreferredInvestmentOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Preferred Investment Options Abstract" } } }, "localname": "ScheduleOfChangesInPreferredInvestmentOptionsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Share Purchase Warrants Table Text Block", "terseLabel": "Schedule of summary of changes in share purchase warrants" } } }, "localname": "ScheduleOfChangesInSharePurchaseWarrantsTableTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "xbrltype": "textBlockItemType" }, "inm_ScheduleOfCommonSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common shares table text block.", "label": "Schedule Of Common Shares Table Text Block", "terseLabel": "Schedule of Private Placement Offering" } } }, "localname": "ScheduleOfCommonSharesTableTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "xbrltype": "textBlockItemType" }, "inm_ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Shares Basic And Diluted Table Text Block", "terseLabel": "Schedule of weighted average number of common shares" } } }, "localname": "ScheduleOfEarningsPerSharesBasicAndDilutedTableTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShareTables" ], "xbrltype": "textBlockItemType" }, "inm_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Inventories Abstract" } } }, "localname": "ScheduleOfInventoriesAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfMinimumLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Minimum Lease Payments Abstract" } } }, "localname": "ScheduleOfMinimumLeasePaymentsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfOptionsActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Options Activity Abstract" } } }, "localname": "ScheduleOfOptionsActivityAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfPrivatePlacementOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Private Placement Offering Abstract" } } }, "localname": "ScheduleOfPrivatePlacementOfferingAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfPropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyAndEquipmentAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfReportableSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Reportable Segments Abstract" } } }, "localname": "ScheduleOfReportableSegmentsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfSummaryOfChangesInSharePurchaseWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Summary Of Changes In Share Purchase Warrants Abstract" } } }, "localname": "ScheduleOfSummaryOfChangesInSharePurchaseWarrantsAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ScheduleOfWeightedAverageNumberOfCommonSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Weighted Average Number Of Common Shares Abstract" } } }, "localname": "ScheduleOfWeightedAverageNumberOfCommonSharesAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_September302022Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September302022 Abstract", "terseLabel": "September 30, 2022:" } } }, "localname": "September302022Abstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "stringItemType" }, "inm_ShareBasedCompensationArrangementAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement aggregate intrinsic value.", "label": "Share Based Compensation Arrangement Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, ending balance" } } }, "localname": "ShareBasedCompensationArrangementAggregateIntrinsicValue", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "monetaryItemType" }, "inm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross", "terseLabel": "Options shares (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, expired/Forfeited", "label": "Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Expired Forfeited", "terseLabel": "Weighted Average Exercise Price, Expired/Forfeited (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceExpiredForfeited", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "inm_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, granted.", "label": "Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Exercise Price Granted", "terseLabel": "Weighted Average Exercise Price, Granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceGranted", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "inm_ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Shares Based Payments Awards Option Outstandings Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Ending balance" } } }, "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentsAwardsOptionOutstandingsWeightedAverageExercisePrice", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "inm_ShareBasedPaymentAggregateIntrinsicValueAtBeginning": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share Based Payment Aggregate Intrinsic Value At Beginning", "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance" } } }, "localname": "ShareBasedPaymentAggregateIntrinsicValueAtBeginning", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "monetaryItemType" }, "inm_ShareBasedPaymentAggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share Based Payment Aggregate Intrinsic Value Granted", "terseLabel": "Aggregate Intrinsic Value, Granted" } } }, "localname": "ShareBasedPaymentAggregateIntrinsicValueGranted", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "monetaryItemType" }, "inm_ShareBasedPaymentNumberOfBalanceAtBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Number Of Balance At Beginning", "periodStartLabel": "Number of shares, Beginning balance" } } }, "localname": "ShareBasedPaymentNumberOfBalanceAtBeginning", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "sharesItemType" }, "inm_ShareBasedPaymentOfNumberOfCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based payment of number of cancelled.", "label": "Share Based Payment Of Number Of Cancelled", "terseLabel": "Number of shares, Cancelled" } } }, "localname": "ShareBasedPaymentOfNumberOfCancelled", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "sharesItemType" }, "inm_ShareBasedPaymentSharesNumberOfGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Shares Number Of Granted", "terseLabel": "Number of shares, Granted" } } }, "localname": "ShareBasedPaymentSharesNumberOfGranted", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "sharesItemType" }, "inm_ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Weighted Average Share Price Balance At Beginning", "periodStartLabel": "Weighted Average Share Price, Beginning balance" } } }, "localname": "ShareBasedPaymentWeightedAverageSharePriceBalanceAtBeginning", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "perShareItemType" }, "inm_ShareBasedPaymentWeightedAverageSharePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment Weighted Average Share Price Granted", "terseLabel": "Weighted Average Share Price, Granted" } } }, "localname": "ShareBasedPaymentWeightedAverageSharePriceGranted", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "perShareItemType" }, "inm_ShareBasedPaymentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payments (Details) [Line Items]" } } }, "localname": "ShareBasedPaymentsDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "inm_ShareBasedPaymentsDetailsScheduleofoptionsactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Options Activity [Abstract]" } } }, "localname": "ShareBasedPaymentsDetailsScheduleofoptionsactivityLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "stringItemType" }, "inm_ShareBasedPaymentsDetailsScheduleofoptionsactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payments (Details) - Schedule of options activity [Table]" } } }, "localname": "ShareBasedPaymentsDetailsScheduleofoptionsactivityTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "stringItemType" }, "inm_ShareBasedPaymentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payments (Details) [Table]" } } }, "localname": "ShareBasedPaymentsDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalAndReservesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital And Reserves [Abstract]" } } }, "localname": "ShareCapitalAndReservesAbstract", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "xbrltype": "stringItemType" }, "inm_ShareCapitalAndReservesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital And Reserves Text Block", "terseLabel": "SHARE CAPITAL AND RESERVES" } } }, "localname": "ShareCapitalAndReservesTextBlock", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReserves" ], "xbrltype": "textBlockItemType" }, "inm_ShareCapitalOfNumberOfBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital Of Number Of Balance", "periodEndLabel": "Number of Ending balance", "periodStartLabel": "Number of Beginning balance" } } }, "localname": "ShareCapitalOfNumberOfBalance", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "sharesItemType" }, "inm_ShareCapitalandReservesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofPrivatePlacementOfferingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofPrivatePlacementOfferingLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofPrivatePlacementOfferingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of Private Placement Offering [Table]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofPrivatePlacementOfferingTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentsinvestmentoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in agents' investment options [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentsinvestmentoptionsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentsinvestmentoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in agents' investment options [Table]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentsinvestmentoptionsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in agents warrants [Table]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinagentswarrantsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinpreferredinvestmentoptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in preferred investment options [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinpreferredinvestmentoptionsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofchangesinpreferredinvestmentoptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of changes in preferred investment options [Table]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofchangesinpreferredinvestmentoptionsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofsummaryofchangesinsharepurchasewarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants [Line Items]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofsummaryofchangesinsharepurchasewarrantsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsScheduleofsummaryofchangesinsharepurchasewarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) - Schedule of summary of changes in share purchase warrants [Table]" } } }, "localname": "ShareCapitalandReservesDetailsScheduleofsummaryofchangesinsharepurchasewarrantsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "stringItemType" }, "inm_ShareCapitalandReservesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Capital and Reserves (Details) [Table]" } } }, "localname": "ShareCapitalandReservesDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "stringItemType" }, "inm_ShareIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share issuance costs.", "label": "Share Issuance Costs", "terseLabel": "Share issuance costs" } } }, "localname": "ShareIssuanceCosts", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "inm_ShareIssuanceCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Issuance Costs Member", "terseLabel": "Share Issuance Costs [Member]" } } }, "localname": "ShareIssuanceCostsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "inm_ShareOfNumberOfCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Of Number Of Cancelled.", "label": "Share Of Number Of Cancelled", "terseLabel": "Number of Cancelled" } } }, "localname": "ShareOfNumberOfCancelled", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "sharesItemType" }, "inm_SharePurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Purchase Warrants Member", "terseLabel": "Share Purchase Warrants [Member]", "verboseLabel": "Share purchase warrants [Member]" } } }, "localname": "SharePurchaseWarrantsMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "domainItemType" }, "inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers", "periodEndLabel": "Number of Ending balance", "periodStartLabel": "Number of Beginning balance" } } }, "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "inm_SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Shares Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Beginning balance (in Dollars per share)" } } }, "localname": "SharesBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "inm_SharesIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issued Member", "terseLabel": "Shares issued [Member]" } } }, "localname": "SharesIssuedMember", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "inm_ShortTermInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investment", "terseLabel": "Cash and cash equivalents and short-term investments" } } }, "localname": "ShortTermInvestment", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Issued For Private Placement.", "label": "Stock Issued During Period Value Issued For Private Placement", "terseLabel": "Private placement" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForPrivatePlacement", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "inm_StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Value Issued For Private Placement Shares.", "label": "Stock Issued During Period Value Issued For Private Placement Shares", "terseLabel": "Private placement (in Shares)" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForPrivatePlacementShares", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "inm_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "inm_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "inm_TotalCommonShareValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total share value.", "label": "Total Common Share Value", "terseLabel": "Total" } } }, "localname": "TotalCommonShareValue", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "monetaryItemType" }, "inm_TransactionCostsAllocatedToAdditionalPaidinCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction costs allocated to additional paid-in capital.", "label": "Transaction Costs Allocated To Additional Paidin Capital", "terseLabel": "Transaction costs allocated to additional paid-in capital" } } }, "localname": "TransactionCostsAllocatedToAdditionalPaidinCapital", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "monetaryItemType" }, "inm_TypeOfCurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Type Of Currency Axis", "terseLabel": "Type Of Currency [Axis]" } } }, "localname": "TypeOfCurrencyAxis", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "stringItemType" }, "inm_TypeOfCurrencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TypeOfCurrency [Domain]" } } }, "localname": "TypeOfCurrencyDomain", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "domainItemType" }, "inm_UnrealizedGainOnForeignExchange": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount Of Unrealized gain on foreign exchange.", "label": "Unrealized Gain On Foreign Exchange", "negatedLabel": "Unrealized foreign exchange loss" } } }, "localname": "UnrealizedGainOnForeignExchange", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "inm_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued.", "label": "Warrants Issued", "terseLabel": "Warrants issued (in Shares)" } } }, "localname": "WarrantsIssued", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "sharesItemType" }, "inm_WarrantsToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants are a derivative that give the right, but not the obligation, to buy or sell a security\u2014most commonly an equity\u2014at a certain price before expiration. The price at which the underlying security can be bought or sold is referred to as the exercise price or strike price.", "label": "Warrants To Purchase", "terseLabel": "Warrants to purchase (in Shares)" } } }, "localname": "WarrantsToPurchase", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "inm_WeightedAverageExercisePriceUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Unvested.", "label": "Weighted Average Exercise Price Unvested", "terseLabel": "Weighted Average Exercise Price, Unvested (in Dollars per share)" } } }, "localname": "WeightedAverageExercisePriceUnvested", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "inm_WeightedAverageExercisePriceVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Vested and exercisable.", "label": "Weighted Average Exercise Price Vested And Exercisable", "terseLabel": "Weighted Average Exercise Price, Vested and exercisable (in Dollars per share)" } } }, "localname": "WeightedAverageExercisePriceVestedAndExercisable", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "perShareItemType" }, "inm_WeightedAverageForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Forfeiture Rate.", "label": "Weighted Average Forfeiture Rate", "terseLabel": "Weighted average forfeiture rate" } } }, "localname": "WeightedAverageForfeitureRate", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "inm_WeightedAverageSharePriceCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Share Price, Cancelled.", "label": "Weighted Average Share Price Cancelled", "terseLabel": "Weighted Average Share Price, Cancelled" } } }, "localname": "WeightedAverageSharePriceCancelled", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "perShareItemType" }, "inm_workingCapitalSurplus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital surplus.", "label": "working Capital Surplus", "terseLabel": "Working capital surplus" } } }, "localname": "workingCapitalSurplus", "nsuri": "http://www.Inmedpharmaceuticalsinc.com/20220930", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r146", "r213", "r214", "r377" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r146", "r213", "r214", "r377" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r87", "r215" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r87", "r92", "r194", "r215" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r87", "r92", "r194", "r215", "r314" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r8", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r148", "r149" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r356", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued Royalties", "terseLabel": "Accrued minimum payments" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r12", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of reclassifications from property, plant and equipment.", "label": "Accumulated Depreciation, Depletion and Amortization, Reclassifications from Property, Plant and Equipment", "terseLabel": "Depreciation expense on property, equipment and leasehold improvements" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r42", "r43", "r44", "r367", "r382", "r383" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r41", "r44", "r50", "r51", "r52", "r79", "r80", "r81", "r270", "r301", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Term of amortization expense" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r79", "r80", "r81", "r253", "r254", "r255", "r276" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Items not requiring cash:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based payment transactions (in Dollars)" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r72", "r171", "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense on intangible assets (in Dollars)" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r77", "r127", "r132", "r139", "r156", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r266", "r271", "r281", "r309", "r311", "r352", "r366" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r32", "r77", "r156", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r266", "r271", "r281", "r309", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-Current" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r217", "r218", "r219", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpenditureDiscontinuedOperations": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of capital expenditure attributable to discontinued operations.", "label": "Capital Expenditure, Discontinued Operations", "terseLabel": "Expenditure" } } }, "localname": "CapitalExpenditureDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r10", "r311", "r385", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and cash equivalents subject to floating interest rates" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r74" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodStartLabel": "Cash and cash equivalents beginning of the period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r74", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents end of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r284" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash during the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r191", "r192", "r193", "r195", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r79", "r80", "r276" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock par value (in Dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".", "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorizedUnlimited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "authorizedUnlimitedItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common shares, no par value, unlimited authorized shares:908,766 (June 30, 2022 - 650,667) issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common Unit, Issued", "terseLabel": "Preferred investment options issued (in Shares)" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r46", "r48", "r49", "r56", "r360", "r374" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Net loss for the period" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r114", "r115", "r146", "r279", "r280", "r388" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r114", "r115", "r146", "r279", "r280", "r384", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r112", "r113", "r115" ], "lang": { "en-us": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer", "terseLabel": "Net sales description" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CUSTOMER CONCENTRATION" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentration" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r61", "r77", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r281" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Gain (Loss)", "terseLabel": "Effect on gain or loss" } } }, "localname": "DebtSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of deferred costs.", "label": "Deferred Costs", "terseLabel": "Unpaid financing costs" } } }, "localname": "DeferredCostsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/NonCashTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r258", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "terseLabel": "Employee compensation, benefits and related accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r72", "r184" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Amortization and depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r126" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Amortization and depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationExpenseOnReclassifiedAssets": { "auth_ref": [ "r182", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).", "label": "Depreciation Expense on Reclassified Assets", "terseLabel": "Amortization expense related to the right-of-use assets" } } }, "localname": "DepreciationExpenseOnReclassifiedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r216", "r217", "r248", "r249", "r251", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED PAYMENTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r1" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Accrued general and administrative expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share for the period" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r84", "r85", "r86", "r87", "r88", "r93", "r95", "r97", "r98", "r99", "r103", "r104", "r277", "r278", "r361", "r375" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, Basic (in Dollars per share)", "verboseLabel": "Basic and diluted loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r84", "r85", "r86", "r87", "r88", "r95", "r97", "r98", "r99", "r103", "r104", "r277", "r278", "r361", "r375" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, Diluted", "verboseLabel": "Basic and diluted loss per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "BASIC AND DILUTED LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/BasicandDilutedLossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost (in Dollars)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r50", "r51", "r52", "r79", "r80", "r81", "r83", "r89", "r91", "r106", "r157", "r210", "r212", "r253", "r254", "r255", "r260", "r261", "r276", "r285", "r286", "r287", "r288", "r289", "r290", "r301", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Issuance of common shares" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r208", "r209", "r275", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetAcquiredInPlaceLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to existing tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.", "label": "Finite-Lived Intangible Asset, Acquired-in-Place Leases", "terseLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetAcquiredInPlaceLeases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted average estimated remaining useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r13", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r172", "r174", "r177", "r179", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r177", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intellectual property" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r172", "r176" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r177", "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Estimated useful life" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Finite-Lived Patents, Gross", "terseLabel": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r282", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r73", "r282", "r283" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "terseLabel": "Foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expenses [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r60", "r77", "r127", "r131", "r135", "r138", "r141", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r281" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross loss" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r127", "r131", "r135", "r138", "r141", "r351", "r358", "r363", "r376" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in non-cash working capital:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r71" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaids and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r170", "r175" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Intellectual property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r362" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Tax expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r30", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r167" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down", "verboseLabel": "Write-down of inventories to net realizable value" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow", "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r63", "r125" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest and other income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total undiscounted lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "terseLabel": "More than five years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofamortizationexpenseTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "terseLabel": "One to five years" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "Less than one year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r77", "r133", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r267", "r271", "r272", "r281", "r309", "r310" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r77", "r156", "r281", "r311", "r353", "r369" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r38", "r77", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r267", "r271", "r272", "r281", "r309", "r310", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r107", "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "CORPORATE INFORMATION AND CONTINUING OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Total cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Total cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r73" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Total cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r45", "r47", "r52", "r55", "r73", "r77", "r82", "r84", "r85", "r86", "r87", "r90", "r91", "r96", "r127", "r131", "r135", "r138", "r141", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r278", "r281", "r359", "r373" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Loss for the period", "verboseLabel": "Net loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r127", "r131", "r135", "r138", "r141" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r297" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r296" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease obligations" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r296" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r196", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Lessee, Operating Lease, Disclosure [Table Text Block]", "terseLabel": "LEASE OBLIGATIONS" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r37", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherMinorityInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of equity interests owned by noncontrolling shareholders, partners, or other equity holders in one or more of the entities consolidated into the reporting entity's financial statements other than joint ventures, limited partnerships, operating partnerships or interests held by preferred unit holders.", "label": "Other Noncontrolling Interests", "terseLabel": "Non-interest bearing" } } }, "localname": "OtherMinorityInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Other Research and Development Expense", "terseLabel": "Accrued research and development expenses" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofaccountspayableandaccruedliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r31", "r357", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-Term Investments", "terseLabel": "Guaranteed investment" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/FinancialRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r67" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Share issuance costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Transaction costs allocated to common shares" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Short-term loan" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaids and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r65" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Shares issued for cash" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Gross proceeds from warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionCosts": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to operate and maintain wells and related equipment and facilities, including depreciation and applicable operating costs of support equipment and facilities and other costs of operating and maintaining those wells and related equipment and facilities. They become part of the cost of oil and gas produced. Examples of production costs (sometimes called lifting costs) are: costs of labor to operate the wells and related equipment and facilities; repairs and maintenance; materials, supplies, and fuel consumed and supplies utilized in operating the wells and related equipment and facilities; property taxes and insurance applicable to proved properties and wells and related equipment and facilities; severance taxes; some support equipment or facilities may serve two or more oil and gas producing activities and may also serve transportation, refining, and marketing activities. To the extent that the support equipment and facilities are used in oil and gas producing activities, their depreciation and applicable operating costs become exploration, development or production costs, as appropriate. Depreciation, depletion, and amortization of capitalized acquisition, exploration, and development costs are not production costs but also become part of the cost of oil and gas produced along with production (lifting) costs identified above.", "label": "Production Costs, Period Cost", "terseLabel": "Materials and equipment at a cost" } } }, "localname": "ProductionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r45", "r47", "r52", "r68", "r77", "r82", "r90", "r91", "r127", "r131", "r135", "r138", "r141", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r265", "r268", "r269", "r273", "r274", "r278", "r281", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net losses" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CorporateInformationandContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r189", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, EQUIPMENT AND ROU ASSETS, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r11", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r187", "r311", "r364", "r370" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, equipment and ROU assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets excluding assets held under lease agreements used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Net, Excluding Capital Leased Assets", "terseLabel": "Property, equipment and ROU assets, net" } } }, "localname": "PropertyPlantAndEquipmentNetExcludingCapitalLeasedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/PropertyEquipmentandRouAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r304", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount of legal services" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r302", "r303", "r305", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": { "auth_ref": [ "r66" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).", "label": "Repayments of Long-Term Capital Lease Obligations", "negatedLabel": "Payments on lease obligations" } } }, "localname": "RepaymentsOfLongTermCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r257", "r346", "r393" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development and patents" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r14", "r75", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Unrestricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r212", "r311", "r368", "r381", "r383" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r79", "r80", "r81", "r83", "r89", "r91", "r157", "r253", "r254", "r255", "r260", "r261", "r276", "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r53", "r77", "r123", "r124", "r130", "r136", "r137", "r143", "r144", "r146", "r156", "r197", "r198", "r199", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r281", "r363" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Pre-funded warrants" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r114", "r146" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of minimum lease payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.", "label": "Schedule of Impaired Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofpropertyandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r127", "r128", "r134", "r169" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r127", "r128", "r134", "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of reportable segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r220", "r236", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of changes in preferred investment options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r120", "r121", "r122", "r127", "r129", "r135", "r139", "r140", "r141", "r142", "r143", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Weighted-average vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value at grant date of options granted (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Weighted average dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted average volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of Expired/Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Number of Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofoptionsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r221", "r223" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Share Price, ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r217", "r218", "r219", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r240", "r241", "r242", "r243", "r244", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Intrinsic value of warrants exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value per share (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Share Price, Cancelled" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Warrants exercisable expire term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Share Price, Ending balance", "periodStartLabel": "Weighted Average Share Price, Beginning balance" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofsummaryofchangesinsharepurchasewarrantsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Common shares (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Issue Price (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r31", "r354", "r355", "r365" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r76", "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r40", "r50", "r51", "r52", "r79", "r80", "r81", "r83", "r89", "r91", "r106", "r157", "r210", "r212", "r253", "r254", "r255", "r260", "r261", "r276", "r285", "r286", "r287", "r288", "r289", "r290", "r301", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentsinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinagentswarrantsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofchangesinpreferredinvestmentoptionsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofreportablesegmentsTable", "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Cash provided by (used in):" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r106", "r347" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Common shares issued (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r77", "r150", "r156", "r281", "r311" ], "calculation": { "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet", "http://www.Inmedpharmaceuticalsinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r291", "r313" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r291", "r313" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofPrivatePlacementOfferingTable" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r208", "r209", "r275", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails", "http://www.Inmedpharmaceuticalsinc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r108", "r109", "r110", "r111", "r116", "r117", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r298", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable operating costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/LeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ShareCapitalandReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r99" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average outstanding common shares, Diluted", "verboseLabel": "Weighted average number of common shares - basic and diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average outstanding common shares, Basic (in Shares)", "verboseLabel": "Weighted average number of common shares - basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement", "http://www.Inmedpharmaceuticalsinc.com/role/ScheduleofweightedaveragenumberofcommonsharesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average outstanding common shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.Inmedpharmaceuticalsinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r397": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r398": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r399": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r401": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r402": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r403": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r404": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r405": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r406": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r407": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 83 0001213900-22-071487-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-071487-xbrl.zip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

Q,H1:[R77N89-2L)P1[]%@Z2#<>]+_PI=J6]3A*=>V. EEL?*_-X;&GU M(+MRJRS4&HVUD.RI&0,)K3T68@E]$&E*E)(M*RC"%_]AF#^P(("=GFQQV989 MV8:(Z>EW+EJVDZPHE,624*Z+7+R]8_$6FE@:Y:K0K&TBEE0E7)1F7O0QEFM5 M5ZT)55!"/N8_X:(WV$W-&I"O;E^DOD. M6(4(F,\[D#W@I>P,:XUF0ZQO6T\>I'J?VCMMI$93J)4KQTCS:NJR?(&?DZ'5 M8X"0,T&^DT++0K55 BN^>J@ 3X Z??$=[>E)U?-RQ%4%D1X&$U?)2W6?DI?\ M3ZN^8E7'A7VKCE4?.OZX*\4=\62QWA7FNJ%1I[ )2;_L9.'2_BR,U<)S_'2] M!>S@X4I-*%76.9A\8!/ZB[# (#R+%I6+ZL_B1%4 Y!?$_6\1)QT5JXVS+WU5 M\PCV8V['#\5P.'U([HJ?88X0K@=R U[_8JHV!6)]T=TYIG-#%QE#I[9W9CPK M77,'D<;"&NO1*ES7%2QK.W_4&G6PP\J1\$=SF3](!_9CJF,'6_0*WK PO],. MEHXC9_%0CLT04OWV/'2;:K)C3(8%5_[SJ_^2QR:O^WY80:7<#(.2+QF/QP:*D M[;IT'S0,&P8&_>:J$C)K!;25(Y*H6WVT;Z:QNSA2K#>$:F537 &[<8) MUJ7TIC/3>'9'KZ8?H]M55\>;#.;LUTB>_:HEH5IJY:C9X,2I-C<=!LT,T6IV MZ/28P.1V]8!_8%3-Q2*;[![-R>WMC/02'.XN5LLEH5%>KVSC!G=.#.YL M$_V!?OT][)I)7^ M(2Y)WUX0PU6 %N"S1O$#\'$[0!);>7P[>]?%IE"I'=5O%KVAM)K(>">TG2%; M?C=%'Z&&XJ?HFE@7JHU2=LS^CPE8_-&T!\^K1\E2]2A;QJ*"5,#F!-ZN')Y+ M<]BNO)7O^M3N_L0N%,!R1YJIMJ2Q(*+BIJ*WLV6S5!8J]:,B1XDV-I\R)9]^ M,W/T]-M"QZ$6V@LZE;;G(ROXC^D;V=KI'+X'\\ 2_[QW@00MJX+7D$P,-F=O MDWXGVCP-I ;20 ><"R3$V\2YI_%X3V4-3!9VYB3^;5V;QG0K28@[=)=0JJT/ M6 JT@^[:[Q%Y];3V"Y).7,^P?CPO!-_F=[H3D[K1"J^+U?0+U!SXS>LYRAPE M!<'I-

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end